NZ613656B2 - Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation - Google Patents

Abstract

The present invention relates to pyrazol-isoxazole compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents. Conditions which may be treated with the compounds include: psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave's disease, rheumatoid arthritis, vitiligo, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjogren's syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis. Compounds of the disclosure include: 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-( trifluoromethyl)-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H -pyrazol-4-yl)-4-( 4-methylthiazol-2-yl)isoxazole, 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-methyl-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4-(furan-2-yl)isoxazole, and 3-(2-chloro-6-fluorophenyl)-5-(I-(3-chlorophenyl)-5-(trifluoromethyl)-IH-pyrazol-4-yl)-4-(1,3,4-thiadiazol-2-yl)isoxazole. mmune thyroiditis, Grave's disease, rheumatoid arthritis, vitiligo, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjogren's syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis. Compounds of the disclosure include: 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-( trifluoromethyl)-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H -pyrazol-4-yl)-4-( 4-methylthiazol-2-yl)isoxazole, 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-methyl-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4-(furan-2-yl)isoxazole, and 3-(2-chloro-6-fluorophenyl)-5-(I-(3-chlorophenyl)-5-(trifluoromethyl)-IH-pyrazol-4-yl)-4-(1,3,4-thiadiazol-2-yl)isoxazole.

Description

IL17 and IFN—gamma inhibition for the treatment of autoimmune inflammation The IL—17 family of cytokines has been associated with the pathogenesis of autoimmune diseases and is lly blamed for the pathogenic symptoms of autoimmune inflammation.

Overexpression of IL—17 is a hallmark for autoimmune diseases like rheumatoid arthritis, systemic lupus erythematomatosus, atory bowel disease, multiple sclerosis, and psoriasis (Yao Z 91‘. £11., I lmmunol, 155(12), 1995, 5483~6. Chang S H, etal, Cytokine, 46, 2009, 7—11; ta Yamada et.al., Journal of . Res, 3, 2010, 33—44)).

The lL—l7 cytokine family comprises six members, out of which iL—17A and IL—17F are the best terized. IL—17A and IL-17F exist as homo— as well as as dimers (IL-17M, IL—ITAF, IL-17FF). IL—17A and IL—17F are clearly associated with inflammation (Gaffen S H, Cytokine, 43, 2008, 402-407; nsky M B et al., Cell. Mol. Life Sci, 67, 2010, 1407- 1421).

The secretion of IL-17 is predominantly caused by a specific subtype of T helper cells termed TH—l7 cells. IL-23, TGFB and IL-6 were shown to be important factors leading to conversion of naive CD4+ T-cells to TH17 cells. It was also reported that TGFB and IL-6 potently induce in synergy TH17 differentiation. ant transcription factors for the secretion of IL—17 from THl7 cells are RORyt and STAT3 (Ivanov,I etal. Cell 126, 2006, 1121-1133). IL-17 induces pro-inflammatory cytokines (IL—6, TNF—u and IL—lb) and Chemokines ,GCP—2,CXCL8 or IL~8,CWC,MCP-l). It increases the production of nitric oxide prostaglandin E2 and matrix-metalloproteinases. As a consequence of these events neutrophil infiltration, tissue damage and chronic inflammation occurs (PECK A et.al., Clin Immunol, 132(3), 2009, 295—304).

Before the recognition of the importance of IL—17 in autoimmune ation, IFngamma derived from THl cells was believed to be an important cytokine that drives autoimmune disorders (Takayanagi H et. al. Nature, 408, 2000, 600—605. Huang W. et. a1. Arthritis Res.

Ther., 5, 2002, R49-R59) The secretion of IFN—gamma is a key feature of the THI effector cell lineage and the secretion is regulated by the ription factors T—bet and STAT4 (Bluestone JA et. al. Nat Rev Immunol, ll, 2009, 811—6). Infiltration of activated T-cells and WO 01263 elevation of M—CSF, IL—10 and TNF support this notion (Yamanda H etal. Ann. Rheu. Dis, 67, 2008, 1299—1304; Kotake S eta]. Eur. J. Immunol, 35, 2005, 3353—3363).

Recently, a more complex ion was proposed, where hybrid THl7/TH1 cells induced by IL~23 and IL—6 in t with lL—l secrete lL—l7 and IFN—gamrna. These cells are under the control of the transcription factors RORyt and T—bet, continuing the notion, that these are true hybrids of "Fill and Tl-Il7 cells. It was also demonstrated that these double producing cells are the pathogenic species in IBD and BAE (Buonocore S eta]. Nature, 464, 2010, 1371—5; Ghoreshi K. et. al. , 467, 2010, 967-971).

Compounds which target and suppress both lL—17 and IFN—gamma are predisposed for the treatment of autoimmune disorders.

The effectiveness of blocking IL—l7 ing as therapeutic treatment in autoimmune es has already been proven in clinical trials with e.g. monoclonal antibodies against IL- l7A (AIN457, secukinurnab; Ly2439821, ixekizumab; RG4934) and/or the IL-l? receptor lL~ l7RA (AMG827, brodalumab). Positive s have been ed for the treatment of rheumatoid arthritis, psoriasis and uveitis (Hueber W et 61]., Sci. Transl. Med, 2, 2010, 52ra72, DOI: 10.1thS/scitranslmed.3001107; van den Berg W B et al., Nat. Rev. Rheumatol., 5, 2009, 549653), ankylosing litis and spondyloarthritides (Song I-H et all, Curr.

Opin. Rheumatol., 23, 2011, 346—351). Secukinurnab is currently under investigation in clinical trials for psoriatic arthritis, Behcet e, uveitits, inflammatory bowel disease, Crohn’s disease, multiple sclerosis (1(0pr er al., Nat. Rev. Drug Disc., 9, 2010, 703-718; Song 1-H et at, Curr. Opin. Rheumatol., 23, 2011, 346-351). Brodalumab, Ixekizurnab and RG4934 are currently in clinical trials for the treatment of rheumatoid arthritis, psoriasis and/or psoriatic arthritis (Kopf M et al., Nat. Rev. Drug Disc, 9, 2010, 703-718; clinicaltrialsgov; Medicines in development for Skin diseases, 2011, hed by PhRMA, wwwphrmacom).

With regard to blocking of IFN—garnrna signaling as therapeutic treatment in autoimmune diseases, the IFN-gamma—specific monoclonal antibody AMGSll is currently under clinical investigations for the treatment of systemic lupus erythematosus (Kopf M et al., Nat. Rev.

Drug Disc, 9, 2010, 703~718).

The present invention relates to a compound of formula (I) Z formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R} is aryl, heteroaryl, cycloalkyl, heteroeyclyl or alkyl, which can be tuted by one or more substituents R’ Ar is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R” ; is aryl, heteroaryl, cycloalkyl or heterocyelyl, which can be substituted by one or more substituents R’; is H, halogen, haloalkyl, alkyl or an alkylester, which can be substituted by one or more substituents R”; R3 independently represents H, -COp_R”, -CONHR”, ~CR”O, R”)2, — SOZNHR”, ~NR”-CO-halealkyl, -NO;_, -NR”-SOz—haloalkyi, —NR”-SOg— alkyl, —SOg-alkyl, -NR”—CO-alkyl, ~CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkoxy, amino, heteroeyclyl, aryl, halearyl, ylalkyl, kyl or heteroaryi; R99 ndently represents H, haloalkyl, hydroxyalkyi, amino, alkoxy, -N=C(R’)2: —NR’-CO—R’, -CR’O, , alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are ally substituted by one or more substituents R’.

The present invention further relates to a compound of formula (I) Z formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl, heteroaryl, lkyl, heteroeyelyl or alkyl, which can be substituted by one or more substituents R’ Ar is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by or more substituents R”; is aryl, heteroaryl, lkyl or heterocyelyl, which can be substituted by or more substituents R’; is H, halogen, haloalkyl or alkyl, which can be substituted by one or more substituents R“; R3 independently represents H, -C02R”, ~CONHR”, ~CR”O, -SOgN(R”)2, n SOzNI-IR”, —NR”—CO—haloalkyl, —N02, ~NR”—SOz-haloalkyl, ~NR”—SO;- alkyl, lkyl, -NR”~CO—alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloagrylalkyl, arylalkyl or heteroaryl; R93 independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, nN=C(R’)2, O—R’, -CR’O, —C02R’, alkyl, lkyl, aryl, haloaryl, ylalkyl, heteroaryl, eyelyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’.

In a red embodiment, the t invention relates to a compound of formula (I) and the pharmaceuticaliy acceptable salt or solvate thereof, wherein RI is aryl, which can be substituted by one or more substituents R’ In a more preferred embodiment, the present invention relates to a compound of formula (I) and the phannaceuticaliy acceptable salt or soIvate thereof, wherein R1 is heteroaryl, which can be tuted by one or more substituents R’ In a more preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein Ar is aryi, which can be substituted by one or more substituents R’ In a more preferred ment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate f, wherein Ar is heteroaryl, which can be substituted by one or more substituents R’ In a more preferred ment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or soivate thereof, wherein Z is aryl, which can be substituted by one or more substituents R’ In a more preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate f, wherein Z is heteroaryl, which can be substituted by one or more substituents R’ In a more preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein Z is heteroeyclyl, which can be substituted by one or more substituents R” In a more preferred embodiment, the t invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein Z is cycloalkyl, which can be substituted by one or more substituents R” In a more preferred embodiment, the present invention relates to a compound of a (I) and the pharmaceutically acceptable salt or solvate thereof, wherein Y is halogen, which can be tuted by one or more substituents R” In a more preferred embodiment, the present invention relates to a compound of a (I) and the ceutically acceptable salt or solvate thereof, Y is haloalkyl, which can be substituted by one or more substituents R” In a more preferred embodiment, the present invention relates to a compound of formula and the ceutieally acceptable salt or solvate thereof, wherein Y is alkyl, which can be substituted by one or more substituents R” In another preferred embodiment, the present invention s to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl, heteroaryl, lkyl, heterocyclyl or alkyl, which can be substituted by one or more substituents R” is aryl or heteroaryl, which can be substituted by one or more substituents R”; is aryl, heteroaryl, cycloalkyl or heterocyclyl, which can be substituted by or more substituents R”; is H, halogen, haloalkyl or alkyl, which can be substituted by one or more substituents R’; R5 independently represents H, , -CONHR”, "CR”O, -SOZN(R”)2, ~ SOgNHR”, O-haloalkyl, -N02, wNR”~SOg-haloallr;yl, —NR”-SOg~ alkyl, ~SOg—alkyl, -NR”—CO—alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, koxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; R33 independently ents H, haloalkyl, hydroxyalkyl, amino, alkoxy, ~N==C(R’)2, —NR’—CO—R’, —CR’O, —COZR’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, aryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally tuted by one or more substituents R”; In another preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl or heteroaryl, which can be substituted by one or more substituents R‘ is aryl or heteroaryl, which can be substituted by one or more tuents R”; is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by or more substituents R”; is H, halogen, kyl, alkyl, which can be substituted by one or more substituents R’; R3 independently represents H, “C02R”, -CONHR”, -CR”O, —SOZN(R”)2, — SOZNHR”, -NR”-CO—haloalkyl, -N02, -NR”~SOz—haloalkyl, OZ- alkyl, ~SOg—alkyl, -NR”—CO-alkyl, ~CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; R93 ndently represents H, haloalkyl, yalkyl, amino, alkoxy, ')2, O—R’, -CR’O, ~C02R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’; In another preferred embodiment, the present invention relates to a compound of formula (I) and the phannaceutically acceptable salt or e thereof, wherein RE is aryl, which can be substituted by one or more substituents R’ is aryl or heteroaryl, which can be substituted by one or more substituents R”; is aryl, cycloalkyl, heterocyelyl or heteroaryl, which can be substituted by or more substituents R’; is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R’; R9 independently represents H, ~C02R”, ~CONHR”, ~CR”O, —SO,2N(R”)2, — SOgNHR”, ~NR”—CO-haloalkyl, -N02, ~NR”—SO;-haloalkyl, -NR”~SOg~ alkyl, —SOz—alkyl, O—alkyl, —CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, , “OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; R95 independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, «N:C(R’)2, —NR’-CO—R’, -CR’0, —C02R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more tuents R”; In another preferred embodiment, the t invention relates to a compound of a (I) and the ceutically acceptable salt or solvate thereof, wherein R1 is heteroaryl, which can be substituted by one or more substituents R” Ar is aryl or heteroaryl, which can be substituted by one or more substituents R”; is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by or more substituents R’; is H, halogen, kyl, or alkyl, which Can be substituted by one or more substituents R’ ; R9 independently represents H, -C02R”, —CONI—IR”, —CR”O, —SC)2N(R”)2, -SOZNHR’ ’, —NR’ “—CO—haloalkyl, —N02, uNR’ ’ -SOz—haloalkyl, OZ—alky1, -SOg-alkyl, —NR”—CO-alkyl, —CN, alkyl, cycloaikyl, aminoalkyi, mino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, kyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; R53 ndently represents H, haloalkyl, hydroxyalkyl, amino, , —N=C(R’)2, -NR’—CO-R’, ~CR’O, —C02R’, alkyl, cycloaikyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are Optionally substituted by one or more substituents R”; In another preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl or heteroaryl, which can be substituted by one or more substituents R” Ar is aryl or heteroaryl, which can be substituted by one or more substituents R’; Z is aryl, cycloalkyl, heterocyclyl or aryl, which can be substituted by one or more substituents R’; Y is H, n, haloaikyl, or alkyl, which can be substituted by one or more substituents R’; R’ independently represents H, —C02R”, -CONHR”, —CR”O, ~SOZN(R”)2, - SOzNHR”, —CN, alkyl, lkyl, aminoalkyl, aIkoxy, ~OH, , hydroxyalkyl, halogen, haloalkyl, koxy, amino, heterocyclyi, aryi, haioaryl, haloarylalkyl, arylalkyi or heteroaryi; R” independently ents H, haloalkyl, hydroxyalkyl, amino, alkoxy, ’)2, —NR’—CO-R’, ~CR’O, —C02R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’ In another preferred embodiment, the present invention relates to a compound of fonnula (I) and the phannaceutically able salt or solvate thereof, wherein R2 is aryl or heteroaryi, which can be substituted by one or more substituents R’; Ar is aryl or heteroaryl, which can be substituted by one or more substituents R’; Z is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more tuents R’; Y is H, halogen, haioalkyl, or alkyl, which can be substituted by one or more substituents R’; R9 independently represents H, —C02R”, -SOgN(R”)2, ~SOgNHR”, -CN, alkyl, , —OI-I, hydroxyalkyl, halogen, haloalkyl, haloalkoxy, cyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or aryl; R33 independently represents H, haloalkyl, yalkyl, amino, alkoxy, -N=C(R’)2, —NR’-CO—R’, —CR’O, —CO;R°, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heteroeyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’ In another preferred ment, the present invention relates to a nd of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is any! or heteroaryl, which can be substituted by one or more substituents R“; Ar is aryl or heteroaryl, "which can be substituted by one or more substituents R”; is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by or more substituents R’; is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more tuents R’; R7 independently represents H, -C02R”, —CONHR”, ~CR”O, —SOgN(R”)2, — SOgNI-IR”, ~CN, alkyl, alkoxy, —OH, halogen, haloalkyl or haloalkoxy,; R95 independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, -N=C(R’)2, —NR’—CO—R’, -CR’O, ~C02R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, kyl or aminoalkyl, which are optionally substituted by one or more substituents R” In another preferred embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically able salt or solvate thereof, wherein R1 is aryl, or aryl, which can be substituted by one or more tuents R’; Ar is aryl or heteroaryl, which can be substituted by one or more substitucnts R”; Z is aryl, lkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R’; Y is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R”; R’ independently represents H, —CO;;R”, -CONHR”, ~CR”O, ~SOZN(R”)2, - SOZNHR”, —CN, alkyl, alkoxy, ~OH, halogen, haloalkyl or haloalkoxy; R” independently represents H, haloalkyl, or alkyl, which can be substituted by one or more substituents R’; In another red embodiment, the present invention relates to a compound of formula (I) and the pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl, which can be substituted by one or more substituents R”; Ar is aryl, which can be substituted by one or more substituents R”; Z is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R’; Y is H, halogen, kyl, or alkyl, which can be substituted by one or more substituents R’; R’ ndently represents H, -C02R”, —CONHR”, ~CR”O, —CN, alkyl, alkoxy, —OH, halogen, haloalkyl or haloalkoxy; R” independently represents H, haloalkyl, or alkyl, which can be substituted by one or more substituents R’; WO 01263 wherein an aryl group denotes an aromatic group having five to fifteen carbon atoms, which may be substituted by one or more substituents R”, and may be fused to another aromatic ring; the aryl group is preferably a phenyl group, ~0—C6H4—R’, -m~C5H4—R’, —p—C5H4~R‘, l—naphthyl,2— naphthyl, l—anthracenyl or 2—anthraceny1; a heteroaryl group denotes a 5— or 6-membered cyclic group which contains at least heteroatom like 0, N, S. This heterocyclic group can be fused to another aromatic ring. For example, this group can be selected from a thiadiazole, thiazol—Z-yl, thiazol-4—yl, thiazol-S—yl, azol—3—yl, isothiazol—4—yl, isothiazol—S-yl, oxazol—Z—yl, 0xazol—4—yl, oxazol—5~yl, isooxazol—3—y1, isooxazol-4uy1, isooxazol—S-yl, 1,2,4-oxadiazol-3—yl, 1,2,4—oxadiazol—5—yl, oxadiazol—3—yl, benzooxazol—Z—yl, benzooxazol-4—yl, benzooxazol—S—yl, benzoisooxazol— 3—yl, benzoisooxazol—4—yl, benzoisooxazol-S-yl, 1,2,5—oxadiazolyl, 1,3,4—oxadiazol-2—yl, 1,2,4—thiadiazoln3nyl, 1,2,4—thiadiazol—5—yi, l,3,4-thiadiazol~2—yl, isothiazol—3-yl, isothiazoiu4— y}, azol-S—yl, benzoisothiazol-3—yl, benzoisothiazol—4-yl, benzoisothiazol-S—yl, 1,2,5— thiadiazol—B—yl, l—imidazolyi, 2-imidazoiy1, 1,2,5—thiadiazol-4—yl, dazolyl, benzoimidazol~4—yl, l-pyrrolyl, 2~pyrrolyl, 3—pyrrolyl, 2—furanyl, nyl, 2-thieny1, 3— thienyl, 2-pyridyl, dyl, 4—pyridyl, 2—pyranyl, 3-pyrany1, 4—pyrany1, Z-pyrimidinyl, 4- pyrirnidinyl, 5—pyrimidinyl, pyrid—Z—yl, pyrid—3—yl, pyrid—4-yl, pyrid—S-yl, pyrid—6—yl, 3— pyridazinyl, 4—pyridazinyl, 2—pyrazir1yl, 1-pyrazolyl, 3—pyrazolyl, 4—pyrazolyl, 1,2,3-triazol—4— yl, 1,2,3—triazol—5—yl, 1,2,4—t1iazol—3-yl, l,2,4~triazolyl, lH—tetrazol—2—yl, 1H—tetrazol—3-yl, tetrazolyl, acridyI, inyl, oiyl, azinyl, indolizine, 2—ir1doly], 3-indolyl, 4— indolyl, 5-ind01y1, 6—indolyl, 7—indoiyl, ndolyl, 3—isoind01yl, 4—isoindolyl, 5—isoindolyl, 6-isoindolyl, 7-isoindolyl, 2—indolinyl, linyl, 4-indoliny1, 5-ind01inyl, 6-indolinyl, 7- indolinyl, benzo[b]fi1ranyl, benzofurazane, benzothiofurazane, benzotriazol-l—yl, benzotriazol-4—yl, benzotriazol—S—yl, benzotriazol—é-yl, benzotriazol—7nyl, benzotn'azine, benzo[b]thiophenyl, benzimidazolyl, benzothiazolyl, quinazolinyl, q'uinoxazolinyl, cinnoline, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, or tetrahydroisoquinolinyl, purine, phthalazine, pteridine, thiatetraazaindene, iazaindene, isothiazolopyrazine, 6- dinyl, 2,4—dimethoxy—6—pyrimidinyl, benzimidazol—Z—yl, 1H—benzimidazolyl, benzimidazol—4—yl, benz~imidazol—5—yl, benzimidazol—6—yl, benzirnidazoLT—yl, tetrazole, tetrahydro—thieno[3,4—djimidazol—2—one, pyrazolo[5,1—c}[l,2,4]triazine, isothiazolopyrimidine, pyrazolotriazine, pyrazolopyrimidine, imidazopyridazine, imidazopyrimidine, imidazopyridine, imidazolotriazine, triazolotriazine, lopyridine, triazolopyrazine, triazolopyrimidine, or lopyridazine group. This heterocyclic group can be substituted by one or more substituents R”, wherein R’ is as defined above; a heterocyclyl group denotes a 3 to 8-membered heterocyclic non—aromatic group which contains at least one heteroatom selected from 0, N, and S, wherein the heterocyclyl group may be fused to another non—aromatic ring and may be substituted by one or more substituents R”, wherein R” is as defined above; the Cg-Cg-heterocyclyl residue may be selected from the group consisting of morphoiine-4—y1, zinyl, isoxazolidine—Z-yl, 1— alkylpiperazine—4—yl, idinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, and l; To keep the definitions as short as possible, in the ing paragraphs “alkyI” is to be understood to encompass alkyi, alkenyl and alkynyl.

In the context of the present invention, an alkyl group, if not stated otherwise, denotes a linear or branched C1—C5-alkyl, preferably a linear or branched chain of one to five carbon atoms; alkenyl group, if not stated otherwise, denotes a linear or branched C2—C6—alkenyl; and an alkynyl group, if not stated otherwise, denotes a linear or branched C2—C5—alkynyl group, which may be tuted by one or more substituents R’.

The C1-C6—alkyl, C2—C6—alkeny1 and C2-C5—a1kynyl e may be selected from the group consisting of —CH3, -C2H5, —CH£CH2, «CECH, «C3H7, 3)2, —CH2-CH£CH2, )=CH2, "CH2CH—CH3, —CEC—CH3, ECH, -C4H9, —CH2-CH(CH3)2, -CH(CH3)— C2H5, -C(CH3)3, -C5H11, ‘C6H139 -C(R’)3, “C2(R’)5= 'CH2"C(R’)3, ~C3(R5)7, ~C2H4-C(R’)3, —C2H4—CH=CH2, —CH:CH—C2H5, —CH=C(CH3)2, -CH2—CH=CH—CH3, —CH£CH—CH:CH2, CECH, —CEC—C2H5, —CH2-CEC-CI-I3, —CEC-CH=CH2, ~CH=CH~CECH, —CEC-CECH, ~C2H4-CH(CH3)2, ~CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, -CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, ~CH2-C(CH3)3, -C3H6—CHECH2, -CH=CH—C3H7, CH=CH—CH3, -CH2—CH:CH—C2H5, ~CH2—CHnCH—CH=CH2, ~CH=CH—CH:CH—CH3, ~CH=CH—CH2—CH:CH2, -C(CH3)=CH~CH=CH2, -CH=C(CH3)-CH=CH2, ~CH=CH—C(CH3)=CH2, -CH2mCH=C(CH3)2, C(cng):C(CH3)2, —C3H6—CECH, m, emit—escorts, "CHg—CEC—Cgl-Is, -CH2—C:—:C-CH=CH2, cag— CH=CH—CECH, -CHg—CEC~CECH, ~CEC~CH=CH—CH3, —CEC~CH3, —CEC- EC~CH3, —CEC-CHg-CH2CH2, —CH=CH-CH2—CECH, ~CEC-CH2—CECH, —C(CH3)zcn—CH=CH2, —CH=C(CH3)—CH:CH2, uCHECH—qcngzcnz, ~C(CH3)-~CH— CECH, —CH=C(CH3)-CECH, -CEC-C(CH3)=CH2, cmcngh, -C2H4-CH(CH3)-C2H5, — )—C4H9, H(CH3)-C3H7, —CH(CH3)-CH2—CH(CH3)2, 3)—CH(CH3)~C2H5, -CH2—CH(CH3)-CH(CH3)2, -CH2-C(CH3)2—C2H5, h—cgng ~C(CH3)2-CH(CH3)2, -C2H4- 3, -CH(CH3)-C(CH3)3, cans—canons -CH=CH—C4Hg, ~C3H5—CH=CH-CH3, CH,— cnzcn—C3H7, -C2H4~CH=CH—C3H5, -CH2—C(CH3)=C(CH3)2, —C2H4~CH-~C(CH3)2, ~C4Hg- CECH, ~CEC-C4H9, —C3H6-CEC-CH3, -CH2-CEC—C3H7, and CEC—C2H5; an arylalkyl group denotes a linear or branched alkyl substituted with at least one aryl group as defined herein. Exemplary arylalkyl groups include benzyl, phenylethyl, 4» hydroXybenzyl, 3-fluorobenzy1, 2-fluoropheny1ethyl, and the like. This arylalkyl group can be ' substituted by one or more substituents R”, wherein R’ is as defined above; a cycloaikyl group denotes a non—aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring may be substituted by a group B, B being 0, S, SO, 802, N, or NR”, R” being as defined above; the C3-Cg—cycioaikyl residue may be selected fiom the group consisting of "OyCIO-CgHs, — cycIo—C4H7, -cyclo—C5H9, -cyclo-C6H1;, —cyclo—C7H13, ~cyclo—C8H15, morpholine—4—yl, piperazinyi, and l-alkylpiperazine—4—yl. This cycloalkyi group can be substituted by one or more substituents R’, n R’ is as defined above; where used, the term “carbocycloalkyl” specifies a non-aromatic ring system comprising three to eight carbon atoms, preferably four to eight carbon atoms, more preferably five to seven carbon atoms, and most preferably six carbons atoms, i.e. a cyclohexyl ring. The carbocycloalkyl group comprises no heteroatoms in the ring. This carbocycloalkyl group can be substituted by one or more substituents R”, wherein R’ is as defined above; where used, the term “heterocycioalkyl” specifies a cycloalkyl group as defined above, wherein one or more of the carbon atoms in the ring are substituted by O, S, SO, 302, N, or NR”, R” being 2012/051360 defined above. Preferred heterocycloalkyl or heterocyelyl are morpholine-4—yl, piperazinyl, and l-alkylpiperazine—4—yl. an alkoxy group denotes an O~alky1 group, the alkyl group being as defined above; the alkoxy group is preferably a methoxy, ethoxy, isopropoxy, tubutoxy or y group; an alkylthio group denotes a S-alkyl group, the alkyl group being as defined above; a haloalkyl group denotes a alkyl group as defined above substituted by one or more halogen atoms, preferably substituted by one to five halogen atoms, the haloalkyl group is preferably a -C(R‘°)3, —CR]°(R10’)2, —CR‘°(R1°')R1””, —C2(R1°)5, -CH2-C(R10)3, ~C(R10’)2-CH(R10’)2, —CH2~ CR1°(R10’)2, w(:i-IZ—CRIO(RIO’)RI0”, ~C3(R10)7, or -C2H4-C(R‘°)3, wherein R1”, R1”; R10” represent F, Cl, Br or 1, preferably F; more preferably, haloalkyl is CF3. a haloaryl group denotes a aryl group as defined above substituted by one or more halogen atoms, ably substituted by one to five halogen atoms; a haloarylalkyl group denotes a linear or ed C1—C5-alkyl substituted with at least haloaryl group as defined herein; a hydroxyalkyl group denotes a HO—alkyl group, the alkyl group being as defined above; a haloalkoxy group denotes an alkoxy group as defined above substituted by one or more halogen atoms, preferably substituted by one to five halogen atoms, the haloalkoxy group is ably a —OC(R1”)3, —OCR1°(R”’°)2, —0CR10(R1°’)R10”, —OC2(R10)5, C(Rw)g, — OCHz—cnlourm’p, wOCHZ—cnmml05R]0", —oc3(R“’)-, or —C(R1°)3, wherein RIO, R"); Rm” represent F, Cl, Br or 1, preferably F; a hydroxyalkylatnino group denotes a (HO—alkyl)2—N— group or HO—alkyl-NH- group, the alkyl group being as defined above; an alkylamino group denotes a HN~alkyl or N-dialkyl group, the alkyl group being as defined above; a halo or halogen group denotes fluorine, chlorine, bromine, or iodine; preferably ne or fluorine; Compounds having infinite chains consisting for instance of repeating R’ and R” units and the like are not assed by this invention. Thus, the longest chain d in each side chain R1, Ar, Z and Y of the compounds according to the invention are three coupled substituents R’ and/or R”, e. g. R’ substituted with R” further substituted with R’ or the like; This is to be understood such that oligomeric or polymeric side chains comprising more repeating R” and/or R” units as above outlined are not within the scope of the present invention.

Constituents which are optionally substituted as stated herein may be substituted, unless otherwise noted, at any chemically possible position.

In the embodiments ofthe present invention, Ar is ably not —§—N x which may be ally substituted and wherein X is N or C and wherein q and r may independently be 0 or 1; furthermore, in the embodiments of the present invention Ar is preferably other than optionally substituted ycloalkyl, more preferably other than Optionally substituted utyl. Thus, ably, the aforementioned groups are excluded by disclaimer from the definition of Ar.

In the embodiments of the present invention, R“ is preferably not CONHR” and/or R” is preferably not aryl. Thus, preferably, the aforementioned groups are excluded by disclaimer from the definition ofAr.

In preferred embodiments of the present invention, Z is selected from the group comprising aryl and heteroaryl, which can be substituted by one or more substituents R’; more preferably Z is phenyl or heteroaryl, which can be substituted by one or more substituents R’; even more preferably 2 is ed from the group comprising phenyl, olyl, thiazolyl, 1,3,4~oxadiazolyl, oxazolyl, 1,3,4—thiadiazolyl, furanyl, and thiophenyl, which can be substituted by one or more substituents R’; even more preferably Z is selected from the group comprising phenyl, tetrazolyl, thiazolyl, 1,3,4—oxadiazolyl, oxazolyl, 1,3,4-thiadiazolyl, l, and thiophenyl, which can be substituted by one or more substituents R”; wherein in the aforementioned preferred embodiments relating to group Z, R: is preferably selected from the group comprising C1_4alkyl, Clu4haloalkyl, hydrogen, hydroxyl, C;_4alkoxy, and C1_4alkoxycarbonyl, more ably methyl, trifluoromethyl, hydrogen, hydroxyl, methoxy, and ycarbonyl and ethoxyoxycarbonyl; yet even more ably Z is selected from the group comprising letetrazol—S—yl, 4~ methylthiazol—Z—yl, thiazol—Z-yl, 5—(trifluoroniethyl)-1,3,4—oxadiazol—2—yl, yl—l,3,4- oxadiazol-Z—yl, 1,3,4-oxadiazol—2—yl, oxazol~5—yl, 4-hydroxy-thiazol—2-yl, 4—methoxy-thiazol— 2—yl, 5—methyl—l,3,4—thiadiazol—2—yl, 1,3,4—thiadiazol—2—yl, furan—B—yl, fiiran—Z-yl, thiophen-B— yl, phenyl, 4—methoxycarbonyl—thiazol—2-yl, and 4—ethoxycarbonyl-thiazol-2—yl; I most preferably Z is selected from the group comprising 4—methylthiazol-2—yl, thiazol—Z—yl, 5- oromethyl)—1,3,4-oxadiazcl—l-yl, 5-methyl-l,3,4-oxadiazol-l—yl, 1,3,4-oxadiazol-l—yl, oxazol-5~yl, 4—methoxy—thiazol—2—yl, 5—methyl-l ,3,4—thiadiazol—2—yl, 1,3,4-thiadiazol—2—yl, furan-B—yl, furan—Z—yl, thiophen—3~yl, , and 4—methoxycarbonyl—thiazol-Z—yi.

In preferred embodiments ofthe present invention, R1 is selected from the group sing aryl which is optionally substituted by one or more substituents R’, aryl which is optionally substituted by one or more substituents R’, cycloalkyl which is optionally substituted by one or more substituents R’, and CMalkyl optionally substituted by a group selected from the group comprising trifluoromethyl, hydroxyl, y, tetrahydropyranyl, morpholinyl, pyridyl , pyridinyl, fluorophenyl and tetrahydrofuranyl; in other preferred ments of the present invention, R1 is ed from the group comprising aryl which is optionally substituted by one or more substituents R’, heteroaryl which is optionally substituted by one or more substituents R’, cycloalkyl which is optionally substituted by one or more substituents R”, and yl optionally substituted by-a group selected from the group sing trifluoromethyl, methoxy, tetrahydropyranyl, morpholinyl, pyridyl and tetrahydrofilranyi; more preferably R1 is selected from the group comprising phenyl which is optionally substituted by one or more tuents R’, pyridyl which is optionally substituted by one or more substinients R’, pyrimidyl which is optionally substituted by one or more substituents R’, thienyl which is optionally substituted by one or more substituents R”, thiazolyl which is optionally substituted by one or more substituents R’, 1,1-dioxo—tetrahydrothienyl, 2,2,2" trifluoroethyl, isopropyl, isobutyl, 2—pipeiidin—4-ylethyl, 2—hydroxyethyl, 2—methoxyethyl, tetrahydropyran—4—yimethyl, 2—morpholinoethyl, pyridin—Z—yimethyl, 2—fluorophenylmethyl, 6—ethoxypyrimidin—4—yimethyl and tetrahydrofuran—Z—ylmethyl; more preferably R1 is selected from the group comprising phenyl which is optionally substituted by one or more substituents R’, pyridyl which is optionally substituted by one or more substituents R”, pyrimidyl which is optionally-substituted by one or more substituents R’, thienyl which is optionally substituted by one or more substituents R”, 1,1—dioxo- tetrahydrothienyl, 2,2,2-trifluoroethyl, isopropyl, yl, 2—methoxyethyl, tetrahydropyran— 4-ylmethy1, 2~rnorpholinoethyh pyridin—Z—ylmethyl and tetrahydrofiiran-Z—ylmethyl; even more preferably R1 is selected from the group sing phenyl which is ally tuted by one or more substituents dually Selected from trifluoromethyl, fluorine, ne, bromine, iodine, nitro, NHZ, -CN, ~NHCO—C1_4-alkyi, inethoxy, C1_4-all<yl, ~802NH2, or -SOZNH—C1_4-alkyl; i which is optionally substituted by one or more of the aforementioned substituents for phenyl; pyrimidyl which is optionally substituted by one or more of the aforementioned substituents for phenyl; thienyl which is optionally substituted by one substituenFCOO—CEw4alkyl; thiazolyl which is optionally substituted by one substituent selected from “COO—Clutaikyl or fluorophenyl; 1,1—dioxo—tetrahydrothienyl, 2,2,2- trifluoroethyl, isopropyl, isobutyl, 2—piperidinylethyl, 2—hydroxyethyl, Z-methoxyethyl, tetrahydropyranmtl—ylmethyl, Z—morpholinoethyl, pyridin—Z—ylmethyl, 2-fluorophenylmethyi, 6—ethoxypyrimidinn4nylmethyl and tetrahydrofiiran—Z-ylmethyi; even more preferably R1 is ed from the group comprising phony} which is optionally substituted by one or more substituents individually selected from trifluoromethyl, fluorine, chlorine, bromine, nitro, NHZ, ~CN, —NHCO—C1_4-alkyl, methoxy, CM—alkyl, 2, or — SOzNH-CIa—alkyl; pyridyl which is optionally substituted by one or more of the aforementioned substituents for phenyl; pyrimidyl which is optionally substituted by one or more of the aforementioned tuents for phenyl; thienyl which is optionally tuted by one substituent—COO—C1-4alkyl; l,l~dioxo-tetrahydrothienyl, trifluoroethyl, isopropyl, isobutyl, Z—methoxyethyl, tetrahydropyranylmethyl, 2—morpholinoethyl, pyridin—Z—ylmethyl and tetrahydrofuran—Z—ylmethyl; yet even more preferably R1 is selected from the group comprising phenyl which is optionally substituted by one or more tuents individually ed from trifluoromethyl, fluorine, chlorine, bromine, iodine, nitro, Nl-lz, —CN, —NHCO—C1.4—alkyl, methoxy, ‘C1_4—alkyl, «SOgNHg, or —SOZNH~C1_4-alkyl; pyrimidyl which is optionally substituted by one or more substituents selected from methyl, y or trifluoromethyl; thienyl substituted by one substituent— COO—methyl, thiazolyl which is optionally substituted by one 'substituent selected from— hyl or 4-fluorophenyl, 1,1—dioxo—tetrahydrothienyl, 2,2,2~trifluoroethyl, isopropyl, yl, 2—piperidin—4—ylethy1, 2~hydroxyethyl, 2—methoxyethyl, tetrahydropyran—4—ylmethyl, 2—rnorpholinoethyl, pyridin—2—ylmethy1, 2—fluorophenylmethyl, 6—ethoxypyriniidin—4—ylmethyl and tetrahydrofuran—Z-ylmethyl; l,l—dioxo~tetrahydrothienyl, 2,2,2—trifluor0ethyl, isopropyl, isobutyl, Z-methoxyethyl, tetrahydropyran-4~ylmethyl, 2—morpholinoethyl, pyridin—Z—ylmethyl and tetrahydrofilran—2—ylmethyl; yet even more preferably R1 is selected from the group comprising phenyl which is optionally substituted by one or more substituents individually selected from fluorine, chlorine, e, nitro, NHQ, -CN, ~NHCO-C1-4—alkyl, methoxy, t-butyl, ~802NH2, or —SOgNH—isopropyl; pyridyl; pyrimidyl which is optionally substituted by one or more substituents selected from methyl or trifluoromethyl; thienyl which is optionally substituted by one substituent—COO— methyl, 1,l—dioxo~tetrahydrothienyl, 2,2,2—trifluoroethy1, isopropyl, isobutyl, oxyethyl, tetrahydropyran~4~ylmethyL 2—morpholinoethyl, n~2~ylmethyl and tetrahydrofuran-Z— ylmethyl; yet even more preferably R1 is selected from the group comprising phenyl, 2—fluor0phenyl, 2- methoxyphenyl, 2—chlorophenyl, ophenyl, 2—iodophenyl, 2—nitrophenyl, 2- cyanophenyl, 2—aminophenyl, 4-trifluoromethoxypheny1, 4—methylsulfonylphenyl, 4» chlorophenyl, 4-fluorophenyl, 4—tertbutylphenyl, 4—nitr0phenyl, ophenyl, 3- trifluoromethylphenyl, 3-fluor0phenyl, 3—chlor0phenyl, 3—cyanophenyl, 4—acetamido—phenyl, 3~acetamido—phenyl, 2—acetamidonphenyl, 3~aminosulfonyl-phenyl, 3- (isopropylamino)sulfonyl-phenyl, 3—nitropheny1, 3—minophenyl, 2,4—difluorophenyl, 2,4— rophenyl, 2,6—dichlorophenyl, 2,3—dichlorophenyl, 3—ch10ro~5-trifluoromethylphenyl, fluorophenyl, 3,5—dichlorophenyl, 2,3,5,6-tetrafluorophenyl, 2-pyridyl; dyl; 4- pyridyl; 4-trifluoromethyl—pyrimid-Z-yl, 6—ethoxyl—pyrimid—4-yl, 2,6-dimethyi-pyrimid-4~yl, Z-methoxycarbonylmthien—3—yl, 4~ethoxycarbonyl~th1'azol—2-yl, 4—(4~flu0rophenyl)thiazol-2—yl, 1,1-di0xo—tetrahydrothienyl, 2,2,2—trifluoroethyl, isopropyl, isobutyl, 2—piperidinylethyl, 2- hydroxyethyl, 2—methoxyethyl, tetrahydropyran—4-ylmethyl, 2—morpholinoethyl, pyridin—Z— ylmethyl, 2~fluorophenylmethyl, 6-ethoxypyrimidin—4—ylmethyl and ydrofilramZ- ylmethyl; 1,1-dioxo—tetrahydr0thienyl, 2,2,2~trifluoroethyl, isopropyl, isobutyl, 2,— methoxyethyl, tetrahydropyran—4—ylmethyl, 2—morpholinoethyl, pyridin—Z—ylmethyl and tetrahydrofuran-2~ylmethyl; yet even more preferably R1 is selected from the group comprising phenyl, 2-flu0rophenyl, 2- methoxyphenyl, 2—chlorophenyl, 2—bromophenyl, ophenyl, ophenyl, 4— henyl, 4—tertbutylphenyl, 3~fluorophenyl, 3-chlor0phenyl, 3-cyanophenyl, 3- acetamido—phenyl, amid0—phenyl, 3—minosulfcnylnphenyl, 3-(isopropylamino)sulfonyl- phenyl, 3~nitr0phenyl, 3—amin0phenyl, 2,4—difluorophenyl, 3,5—difluorophenyl, 3,5- dichlcrophenyl, 2,3,5,6-tetrafluorophenyl, dyl; 3—pyrldyl; 4-pyridyl; 4- trifleoromethyl- d—Z—yl, 2,6udimethyl—py1imid4-yl, 2~methoxycarbonyl-thien—3 —yl, 1,1—dicxo— tetrahydrothienyl, 2,2,2-t1‘ifluoreethyl, isopropyl, isobutyl, Z—methoxyethyl, tetrahydropyran— ethyl, 2—(morpholin~4—yl)—ethyl, and tetrahydrofuran-Z—yl—methyl; yet even more preferably R1 is selected from the group comprising phenyl, Z-fluorcphenyl, 2» chlorophenyl, 2mmeth0xyphenyl, 2—nitr0phenyl, 2—aminophenyl, 4—flu0r0phenyl, 3~ fluomphenyl, 3-chlor0phenyl, 3—cyanopheny1, 3~acetamido—phenyl, 3—nitrophenyl, 3— aminophenyl, 3,5—difluorophenyl, 3,5—dichlor0phenyl, Empyridyl; 3-pyridyl; 4—pyridy1; 2- methoxycarbonyl—thien~3~y1, 2,2,2—trifluoroethyl, yl, and tetrahydrofuran-Z—y1—methyl; yet even more preferably R1 is selected from the group comprising phenyi, Z-fluorophenyl, 2— chlorophenyi, 3-fluorophenyl, 3—chloropheny1, 2—pyridyl; 3—pyridyl and 4—pyridyl.

In preferred embodiments of the present invention, Ar is selected fiom the group comprising phenyl and pyridyl, which can be substituted by one or more substituents R’; more preferably Ar is selected from the group sing phenyl and pyridyl, which can be substituted by one or more substituents independently selected from fluorine, methoxy or chlorine; also more preferably Ar is selected from the group comprising phenyl, fluorophenyl, 2- -6—fluorophenyi, 2—ch10ro—6-methoxyphenyl, 2~fluorophenyL 3-fluorophenyl, 2— chlorophenyl, 4—chlorophenyl, 4—n1ethoxyphenyl, 2,6—dichlorophenyl, 3,4-dichlorophenyl, 2,4wdichlorophenyl, 3ufluoropyridin—4—y1, 3,5—dichloropyridin—4—yl and 3-chloro—5— fluoropyridinyl; even more preferably Ar is selected from the group comprising , 2—chloro—6- fluorophenyl, ophenyl, 2—chlorophenyi, 2,6—dichlorophenyl, 2,4—dichloropheny1, 3— fluoropyridin—él—yl, 3,5—dichloropyridinyl and 3-ch]oro—S—fluoropyridin—4—y1. even more preferably Ar is selected from the group comprising 2~chloro—6-fluorophenyl, and 2*chloro—6—methoxyphenyl.

In preferred embodiments of the present invention, Y is selected from the group comprising H, haloalkyi, and alkylester= which can be substituted by one or more substituents R’; more ably Y is selected from the group comprising H, and haloaikyl which can be tuted by one or more substituents R’; more preferably Y is selected from the group comprising H, uoroethyl, trifluoromethyi and methoxycarbonyi; even more ably Y is selected from the group comprising H, trifluoromethyl and methoxycarbonyl; even more preferably Y is trifluoromethyl.

In preferred embodiments of the present invention, R’ is independently selected from the group comprising H, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, morpholinyl, piperazinyl, cyclohexyl, pyrrolidinyl, CF3, F, Cl, Br, methoxy, tetrahydropyranyl, isoxazolidinyl, nitro, ~NH2, ido, -SOZNH2, ~SOgNHiPr and COO-methyl; more preferably R” is independently selected from the group comprising H, methyl, ethyl, propyl, butyl, isopropyl, tert—butyl, CF3, F, C1, methoxy, tetrahydropyranyl, isoxazolidinyl, nitro, —NH2, and —COO~methyl.

In preferred embodiments of the present invention, R” is independently selected from. the group comprising H, trifluoromethyl, methoxy, NH;, and methyl.

Particularly preferred nds of the present invention are the compounds of the below examples of the present invention, more ably the compounds of below examples 4, 5, 6, 7, 8, 10, 11, 12, 14, 16, 17, B—2, B—3, B—4, B-S, B~6, 13-7, 3—8, 3—9, B-lO, B-21, B-22, B-24, B—25, B—26, B—27, and B—30, most preferably the compounds ofbelow examples 4, 5, 7, 8, 16, 17, 8—3, B—4, B—S, B—6, 13—7, and B-8.

It is apparent that the aforementioned preferred embodiments regarding the residues X, Y, Ar, R], R’ and R” may be combined to yield r more preferred ments. Some examples of such ations are, without limiting the invention to these particular combinations: A nd according to the present invention, n R1" is selected from the group comprising phenyl which is optionally substituted by one or more substituents individually selected fiom trifluoromethyl, fluorine, chlorine, bromine, nitro, NI-lg, —CN, —NHCO—C1_4~alky1, methoxy, C1_4—alky1, - SOgNHg, or ~SOgNH—C14-a1ky1; pyridyl which is ally substituted by one or more of the aforementioned tnents for phenyl; pyrimidyl which is optionally substituted by one or more of the aforementioned substituents for phenyl; thienyl which is optionally substituted by one substituent—~COO-C1_ 4alkyl; l,1—dioxo-tetrahydrothienyl, 2,2,2—trifluoroethyl, isopropyl, isobutyl, 2~ methoxyethyl, tetrahydropyran~4~ylmethyh Z—morpholinoethyl, pytidin—Zw ylmethyl and tetrahydrofuranQ—ylmethyl; Ar is selected from the group comprising phenyl and pyridyl, which can be substituted by one or more substituents independently selected from fluorine methoxy or ne; Y is selected from the group comprising H, trifluoromethyl and l 0 methoxycarbonyl.

A compound according to the present invention, wherein R1 is selected from the group comprising phenyl which is optionally substituted by one or more snbstituents individually ed from fluorine, chlorine, bromine, nitro, NHg, —CN, mNHCO-C1_4—alkyl, y, t—butyl, -SOgNH2, or ~802NH— isopropyl; pyridyl; pyrimidyl which is optionally substituted by one or more substituents selected from methyl or trifluoromethyl; thienyl which is optionally substituted by one substituent—COO-methyl, 1,1—dioxo— tetrahydrothienyl, 2,2,2—trifluoroethyl, isopropyl, isobutyl, Z—methoxyethyl, tetrahydropyran—4—ylmethyl, 2—morpholinoethyl, pyridin—Z—ylmethyl and tetrahydrofuran-Z-ylmethyl; Ar is ed from the group comprising , 2,6—difluorophenyl, chhloro—é— fluorophenyl, 2-chloro—6-1nethoxyphenyl, 2—fluorophenyl, 2—chlorophenyl, 2,6- dichlorophenyl, 2,4-dichlorophenyl, 3—flu01‘0pyridinm4—yl, 3,5~dichloropyridin— 4~yl and 3,5—diflu0ropyridin—4—yl; Z is selected from the group sing phenyl, tetrazolyl, thiazolyl, 1,3,4— oxadiazolyl, oxazolyl, 1,3,4—thiadiazolyl, furanyl, and thiophenyl, which can be substituted by one or more substituents selected from the group comprising methyl, trifluoromethyl, en, hydroxyl, y, and methoxycarbonyl and ethoxyoxycarbonyl; Y is selected from the group comprising H, tiifluoromethyl and methoxycarbonyl.

A nd according to the present invention, wherein R] is selected from the group comprising phenyl, ophenyl, 2~ methoxyphenyl, 2—chloropheny1, 2-bromophenyl, 2—nitrophenyl, 2~ aminophenyl, 4—fluor0phenyl, 4~tertbutylphenyl, 3-fluorophenyl, 3- chlorophenyl, 3-cyanophenyl, 3-acetamido-phenyl, 2—acetaniido—phenyl, 3— aminosulfonyl-phenyl, 3-(isopropylarnino)sulfonyl-phenyl, 3—nitrophenyl, 3- aminophenyl, 2,4~difluorophenyl, 3,5—difluorophenyl, 3,5—dichlorophenyl, 2,3,5,6—tetrafluorophenyl, 2—pyridyl; dyl; 4—pyridyl; 4- trifluoromethyl- pyrimid-Z-yl, methy1—py1‘imid—4—yl, 2-methoxycarbonyl—thien—3-yl, 1,}- dioxo—tetrahydrothienyl, 2,2,2—trifluoroethy1, pyl, isobutyl, 2— methoxyethyl, tetrahydropyran—4-yl—methyl, 2—(morpholin—4—yD-ethyl, and ydrofiiran—Z—yl-methyl; Ar is selected from the group comprising phenyl, 2-chloro-6nfluorophenyl, 2- fluorophenyl, Z—chlorophenyl, 2,6—dichlorophenyl, 2,4—dichlorophenyl, 3— fluoropyridin—filnyl, 3,5—dichloropyridin—4-y1 and 3,5«difluoropyridin—4~yl; Z is selected from the group comprising lH—tetrazol—S—yl, 4-methy1thiazolu2-yl, thiazoI—SZ-yl, 5—(trifluoromethyl)—1 ,3 ,4-oxadiazolu2—yl, 5—methyl-1,3,4- oxadiazol~2~yl, l,3,4-oxadiazol—2~yl, —S—yl, 4—hydroxy—thiazol—2—yl, 4- methoxy—thiazol-Z-yl, 5—methyl—1,3,4~thiadiazol-2—yl, 1,3 adiazol~2—y1, furan—3-yl, Z—yl, thiophen—3—yl, phenyl, 4—methoxycarbonyl—thiazol-Z~y1, and 4-ethoxycarbonyl-thiazol—2—y1; Y is selected from the group comprising H, trifluorornethyl and methoxycarbonyl.

According to expert's knowledge the compounds of the invention as well as their salts may contain, e.g. when isolated in lline form, varying amounts of solvents. Included Within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of a (I) as well as all solvates and in particular all hydrates of the salts of the compounds of formula (I).

As used herein the terms disease, indication and medical condition are used interchangeably.

The t invention further s to a method of treatment for a disease or a therapeutic indication in which the inhibition of interleukin-17 (IL-17) and/or Interferon-γ (INF-γ) is beneficial, or for a disease or indication selected from the group consisting of psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave’s e, rheumatoid arthritis, vitiligo, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, le sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet e, atopic dermatitis, Lichen planus, Sjögren’s syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis, wherein the method comprises administering to a subject in need thereof an effective amount of a compound of formula (I). Analogously, the present invention further relates to methods as the one described above, which ass the further embodiments bed herein, in particular the preferred compounds, l uses and compounds for use in l treatments as described herein.

The present invention further relates to pharmaceutical compositions, kits and kits-of parts comprising the compounds according to the present invention.

The present ion further relates to the use of the compounds according to the present invention for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis of the diseases, disorders, illnesses and/or conditions as mentioned .

In a particular ment, the present invention further relates to the use of the compounds according to the present invention, and of their pharmacologically tolerable salts, in the manufacture of a medicament for use in treatment of a disease or a therapeutic indication in which the inhibition of interleukin-17 (IL-17) and/or eron-γ (INF-γ) is beneficial.

The t invention further relates to the methods and medical uses described , encompassing the pharmaceutical compositions as described herein.

The pharmaceutical compositions as described herein comprise one or more of the compounds ing to this invention and a pharmaceutically acceptable carrier or diluent.

WO 01263 2012/051360 onally, the invention relates to an article of manufacture, which comprises packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective against the medical conditions as described herein, and wherein the packaging material comprises a label or package insert which indicates that the pharmaceutical agent is useful for preventing or treating said medical conditions, and wherein said pharmaceutical agent comprises one or more compounds of a (1) according to the invention. The packaging material, label and package insert ise parallel or resemble what is generally regarded as standard packaging material, labels and package inserts for ceuticals having related utilities.

The pharmaceutical compositions according to this invention are prepared by processes which are known per se and familiar to the person d in the art. As pharmaceutical compositions, the compounds of the invention (= active compounds) are either employed as such, or preferably in combination with suitable pharmaceutical auxiliaries and/or excipients, e.g. in the form of tablets, coated s, capsules, caplets, suppositories, patches (eg. as TTS), emulsions, suspensions, gels or solutions, the active compound content ageously being between 0.1 and 95% and where, by the appropriate choice of the auxiliaries and/or excipients, a pharmaceutical administration form (e.g. a delayed release form or an enteric form) exactly suited to the active compound and/or to the desired onset of action can be achieved.

The person skilled in the art is familiar with auxiliaries, vehicles, excipients, diluents, carriers or adjuvants Which are suitable for the desired ceutical formulations, preparations compositions on account of his/her expert knowledge. In addition to solvents, gel formers, ointment bases and other active compound excipients, for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers, colorants, complexing agents or permeation promoters, can be used. ing upon the particular disease, to be treated or prevented, additional therapeutic active agents, which are normally administered to treat or t that disease, may optionally be coadministered with the nds ing to the present invention. As used , additional therapeutic agents that are normally administered to treat or prevent a particular disease are known as appropriate for the disease being treated.

In a further aspect of the present invention, the compounds according to this invention or the salts of said compounds of formula (I), may be combined with standard eutic agents which are commonly used for the treatment ofthe medical ions as described herein.

The person skilled in the art is aware on the base ofhis/her expert knowledge of the total daily dosage(s) and administration form(s) of the additional therapeutic s) coadministered.

Said total daily dosage(s) can vary within a wide range. In practicing the present invention and depending on the details, characteristics or purposes of their uses mentioned above, the compounds according to the t invention may be administered in combination therapy tely, sequentially, simultaneously or chronologically red (e.g. as combined unit dosage forms, as separate unit dosage forms or a adjacent discrete unit dosage forms, as fixed or nonfixed combinations, as kit—of-parts or as admixtures) with one or more standard therapeutics, in particular art—known chemotherapeutic or target specific anti—cancer agents, such as those mentioned above.

Thus, a further aspect of the present invention is' a combination or pharmaceutical ition comprising a first active ingredient, which is a compdund according to this invention or a salt f, a second active ingredient, which is an art—known standard therapeutic for the medical conditions as described herein, and optionally a pharmacologicaily acceptabie carrier, diluent and/or excipient for sequential, separate, simultaneous or chronologically staggered use in therapy in any order, e. g. to treat, prevent or ameliorate in a patient the medical conditions as described herein.

In this context, the present invention further relates to a combination comprising a first active ingredient, which is at least one compound according to this invention, and a second active ient, which is at least one art—known standard therapeutic for the medical conditions as described herein, for separate, sequential, simultaneous or chronologically staggered use in therapy, such as e. g. in y of those diseases mentioned herein.

The term “combination” according to this invention may be t as a fixed combination, a non—fixed combination or a —parts. A “fixed combination” is defined as a ation wherein the said first active ingredient and the said second active ingredient are t together in one unit dosage or in a single entity. One example of a “fixed combination” is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture for simultaneous administration, such as in a ation.

Another example of a “fixed combination” is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.

A “kit—ofrparts” is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a “kit—of— parts” is a combination wherein the said first active ingredient and the said second active ingredient are present tely. The components of the kit—of—parts may be administered Separately, sequentially, simultaneously or chronologically staggered.

The first and second active ingredient of a combination or kit—of—parts ing to this invention may be provided as separate formulations (i.e. independently of one r), which are subsequently brought together for simultaneous, sequential, separate or chronologically staggered use in ation therapy; or packaged and ted together as separate components of a combination pack for simultaneous, sequential, te or chronologically staggered use in combination therapy.

The type of ceutical formulation of the first and second active ingredient of a combination or kit-ofparts according to this invention can be similar, i.e. both ingredients are formulated in separate tablets or capsules, or can be different, i.e. suited for different administration forms, such as e. g. one active ingredient is formulated as tablet or capsule and the other is formulated for e. g. intravenous administration.

The amounts of the first and second active ingredients of the ations, compositions or kits ing to this invention may together comprise a therapeutically effective amount for the treatment, prophylaxis or amelioration of a l condition as described herein A further aspect of the present invention is a method for treating cotherapeutically the medical conditions as described herein, in a patient in need of such treatment comprising stering separately, sequentially, simultaneously, fixed or non—fixed a pharmacologically active and eutically effective and tolerable amount of one or more of the compounds according to the present invention and a pharmacologically active and therapeutically effective and tolerable amount of one or more art-known therapeutic agents for the medical conditions as bed herein, to said patient.

For the production of the pharmaceutical compositions, the compounds of the invention (= active compounds) are preferably mixed with suitable pharmaceutical auxiliaries and filrther processed to give suitable ceutical ations. Suitable ceutical formulations are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.

The pharmaceutical compositions according to the invention are prepared by processes known per se.

The dosage of the active compounds is carried out in the customary order of ude.

Topical application forms (such as ointments) thus contain the active compounds in a concentration of, for example, 01—99%. The customary dose in the case of ic therapy (p.o.) is usually between 0.3 and 30 mg/kg per day, (i. V.) is usually between 0.3 and 30 mg/kg/h. The choice of the optimal dosage regime and duration of medication, particularly the optimal dose and manner of administration of the active compounds necessary in each case can be determined by a person skilled in the art on the basis of his/her expert knowledge.

A method for synthesis of the nds of the formula (I) comprises the step of ng a nitriloxyde with an acetoacetate, haloalkene or methylcrotonate to obtain a methyl—isooxazole derivative (Hanson JC 6151!. J Chem Soc 1965, 5976—5979, Lasri J et. a]. J Heterocyclic Chem, 45,2008, 1385—1389). Nitriloxydes are ed from aldehydes by the reaction of hydroxylamine (II) to obtain oxiines (Cheng FK er. al. Bioorg Med Chem Lett 2006, 16, 3376. Oximes are reacting with n—Chlorsuccinimide to obtain the corresponding chlorooxime (HI) (Balachandran S et. a1. Bioorg Med Chen Lett. 19, 2009, 776).

Scheme(1) __,._ F or —> F CI F CI \ \ \ O N~OH Cl N—OH I II III The oxime (III) is used in situ to form the nitriloxyde (IV) and a cycloaddition to the appropriate dipoiarophile yields the appropriate 3«phenyl-S—methylisoxazole (VI).

WO 01263 Scheme (2) F CI < F —..+ ‘\ II Cl N-OH I? III IV V VI The isooxazole product (VI) can be converted with Bredereck’s reagent (VIII) in refluxing toluene to the appropriate enamine (IXa) (Bredereck H et, a1. Chem Ber 101, 1968, 41—50).

This enamine compound (IXa) is d with a acid anhydride or an appropriate activated acid (X) to the key intermediate phenyl"dimethylamino~trifluoro—oxobuteneyl—isoxazol (XIa).

This intermediate is heated with a substituted hydrazine (XII) to obtain the pyrazol (XX). fication of the ester (XX) (methyl or ethyl) yields the ponding free acid (XXI), which is converted to the amide (XXII) by coupling reaction with ammoniumhydrochloride, HBTU (2-(1H~benzotriazol—l-yl)—1,1,3,3—tetramethyluronium hexafluorophosphate) and base (DIEPA) in DMA as solvent (Fields CG. etal. Peptide Research, Vol. 4, 1991, 95—101). The amide is converted to the thionamide with Lawesson's reagent in dioxane as solvent (Thomsen, 1.; Clausen, K.; Scheibye, 8.; Lawesson, S.-O., Org. Synth, Coll. Vol. 7, 1990, 372). The mide (XIX) is converted to the thiazole (compound 5) with 1,2—dichloro-l— ethoxyethane according to er, I., Pries, H., Roesch, D., Malewski, G., Journal fuer Praktische Chemie (Leipzig), Volume 317, Issue 6, 1975, 953—8.

WO 01263 Scheme (3) (3K 0 toluene F CI 0 F >LO E2026”; reflux + + ll \ CH3 \NAN/ N ‘ I N-O I I 0 Cl IV V VI VIII ethanol reflux DIPEA XIa XII Lawesson's reagent / It" dioxane ’N F S e N Compound 5 (Table 3) The class of compounds of the present invention is useful for the development of immunomodulatory and anti—inflammatory medicaments or, more generally, for the treatment of diseases where the inhibition of eukin—l7 (IL—l7) and/or Interferon—y (INF—y) is beneficial.

The nds of the present invention are also useful for the ent of diseases which are related to or mediated by atory nes, such as psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave’s disease, rheumatoid arthritis, vitiligo, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type 1, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjogren’s syndrome, spinal disc herniation, acne, Graft» versus—Host—Reaction, Host —versus~Grafi—Reaction and osteoarthritis Examples The following compounds were purchased: 1. tert-Butoxy—bis(dimethylamino)methan o Scientific Ltd, UK) 2. Methyl 3~(2-chlorofluorophenyl)—5-methylisoxazole—4—carboxylate (Apollo Scientific Ltd, UK) 3. 3~(2—chloro~6-fluor0phenyl)—5—methylisoxazole—4-carbonitrile (Fisher Scientific GmbH, UK) amin hloride (Sigma Aldrich Chemie GmbH, Germany) 9.00:4?“th 2-ch10rofluorobenzaldehyde oxime (Fisher Scientific Gmbl—I, UK) N—Chlorosuccinimide, NCS (Acros cs BVBA, Belgium) Ethyl acetoacetate, Methyl acetoacetate (Sigma Aldrich Chemie GmbH, Germany) Trifiuoroacetic anhydride (Sigma Aldrich Chemie GmbH, Germany) 2-(1H—Benzot1iazole-l—yl)—l ,l,3,3—Tetramethyluronium hexafluorophosphate, HBTU (Iris Biotech GmbH, Germany) . Hydroxybenzotriazole, HOBT (Sigma Aldrich Chemie GmbH, Gennany) 1 1. Methyl 3—(2-chloro~6—flu0r0phenyl)—5—[2—(dimeth-ylarnino)—1 —(2-ethoxy—2— oxoacetyl)vinyl]—4—isoxazolecarborylate (Key Organics Ltd, UK) 12. l~(3~dimethylamin0propyl)—3—ethylcarbodiimide hydrochloride, EDC (Sigma Aldrich Chemie GmbH, Germany) 13. Hydrazines (ABCR GmbH & Co. KG, Germany) 14. Solvents generally (Sigma Aldrich Chemie GmbH, Germany) . N,N—Diisopropy1ethylamine, DIPEA (ACROS Organics, Belgium) 16. Ammoniumchlorid p.a. (Sigma Aldrich Chemie GmbH, Germany) 17. 2,4—bis(4—methoxyphenyl)-l ,3,2,4—dithiadiphosphetane sulfide, Lawesson’s Reagent (Sigma Aldrich Chemie GmbH, Germany) 18. 1,2-Dichloroethyl ethyl ether (ABCR Gran & Co. KG, Germany) 19. Natriumazid (ACROS Organics, Belgium) . N,O—Dimethylhydroxylamine (ChemPur GmbH, y) 21. Lithium aluminium hydride (Sigma Aldrich Chemie GmbH, y) 22. ethyl isocyanide, ToleC (ACROS Organics, Belgium) Synthesis of compounds of formula 11! General procedure for the preparation of 5—methylisoxazole—4wcarboxylate, exemplarily shown for Ethyl 3-(2-chloro—G—fluorophenyl)—5-methylisoxazole—4—carboxylate H N 0 H C OR 0R1 NH20H*HCI if”0 Cl 3 x 101 1 H A CH3 A R l\I‘I __ "mm—"'“ R \N R O O DMF 5H Na R \N’ HCE EtOH EtZO A B C D H age -.

F F oveaa ; ' .. owe a i: W my, ”‘5 W ‘- o o l ‘ . ‘1" f- eIUH Dram—tel will-l Na, slot-1, 5120 To a stirred mixture of aldehyde A (5 g, 31,5 mmol), l (10 mL), ice and water (30 mL) and hydroxylamine hydrochloride (2.8 g, 40.3 mmol), an aqueous solution of NaOH (3.6 g, 90 mmol in 5 mL of water) was added. The mixture was stirred for an hour and extracted with 40 mL of ether to remove impurities. The aqueous layer was neutralized with HCl and extracted with ether (2x50mL). Extracts were dried over Na2804 and evaporated to give 5.19g I of oxime B (yield 93%).

To a solution of aldoxime B (2 g, 11.5 mmol) in 10 mL of DMF, 0.23 g (1.72 mmol) of N~ chlorosuccinimide (NCS) were added at room temperature. Dry en chloride was d into the DMF solution until the reaction temperature rose up to 35°C. Then 1.31 g (9.8 mmol) of NCS was added portionwise, the temperature was kept at 35-4500 The reaction mixture was cooled to room temperature and poured onto 30 IIIL of ice and extracted with ether. ed extracts were dried and ated to give 2.5 g of hydroxamoyl chloride C as a yellow oil.

A solution of ethyl sodium acetoacetate [from sodium (0.3 g, 13 mmol), dry ethanol (10 mL) and ethyl acetoacetate (1.7 g, 13 mmol)] was added slowly to a stirred solution of the hydroxamoyl chloride C (2.5 g, 12 mmol) in 20 mL of ether at 0-3°C. The mixture was allowed to warm to room temperature overnight, and the solvent was evaporated in vacuo.

The residue was taken up with water and ether, the ether extract was evaporated and the product was purified by column chromatography (hexane) to give 2.2 g of the isoxazole derivative D as a colorless oil.

Ethyl 3-(2—chloro—6—fluorophenyl)methylisoxazoIe—4—carboxylate, oil, yield 67% Result of LC/MS [M+H]+: 283.95 IH NMR (DMSO~D6, CCl4): 1.06 (3H, t, CH3), 2.78 (3H, s, CH3), 4.09 (2H, q, CH2), 7.26 (1H, t, CHharom.), 7.39 (1H d, CH—arorn.), 7.55 (1H, m, CH- arom.) Analoguously prepared: Ethyl 3—(2,4-dichlor0phenyl)—5-methylisoxazolecarboxylate, oil, yield 82% 1H NMR (DMSO'Dfi, CCl4): 1.10 (3H, t, CH3), 2.74 (3H, s, CH3), 4.10 (2H, q, CH2), 7.42 (1H, d, m.), 7.47 (1H dd, CH-arom.), 7.59 (1H, (1, CH— atom.) Methyl 3-(4-methoxyphenyl)methylisoxazolecarboxylate yield 65% 1H NMR (DCCI3)? 2.71 (3H, s, CH3), 3.79 (3H, s, OCHg), 3.85 (3H, s, OCH3), 6.97 (2H, AB— syst., CH—arom.), 7.60 (2H AB~syst., CH—arorn.).

Methyl 3—isopr0pyE—S-methylisoxazoIe—4-carboxylate, oil, yield 64% 1H NMR (DMSO—Dé, CC14): 1.26 (3H, s, CH3), 1.27 (3H, s, CH3), 2.62 (3H, s, CH3), 3.37 (1H, m, CH—i—Pr.), 3.81 (1H s, OCHg).

Synthesis of methyl 3-(2-chlorofluorophenyl)—5-(2-(dimethylamino)vinyl)isoxazoIe-.4- carboxylate \O F O O F / O \ 0+ toluene I / \N/ + N_< \ \ N / NW 6 h reflux t\\t'O \ c: / e: To a on of 0.1 g (0.3708 mmol) methyl 3"(2—ehloro—6—fluorophenyl)—5-methylisoxazole— oxylate in 10 mL dry toiuene, 0.15 1111. (0.7417 mmol) terthutoxy— bis(dimethylamino)methane reck’s t) were added. The reaction mixture was heated under reflux for 6 h.

The mixture was concentrated in vacuo and was dried in high vacuum. Petroleum ether was added to the oily residue and crystalline product ped. The product was collected by filtration, and 0.070 g (yield of theory: 58%) of the vinyl isoxazole derivative were obtained.

Result of LC/MS [M+H]+: 325.0; IIt! NMR (DMSO-dfi; CC14): 3.02 (6H, s, N-CHg), 3.53 (3H, s, CH3), 5.54-5.58 (1H, (1, CH), 7.72—7.76 (1H, d, CH), 7.32—7.38 (1H, dd, CH~arom.), 7.44- 7.47 (1H, d, CH—arom.), 7.56-7.58 (1H, d, CH-arom.) sis of methyl 3-(2-chlore-6—fluorophenyl)—S-(1—(dimethylamino)—4,4,4—trifluoro—3- oxobuten-Z-yl)isoxazoIe—4-carboxylate o F C10 F F '31 0 + dry DCM \ x \ F —_’_" \ O O 3 h N“o F To a solution of 0.5 g (1.53 97 mmol) methyl hloro—6—fluoropheny1)~5—[2— (dimethylaminc) vinyl]isoxazole~4mcarbcxylate in 20 ml. dry dichloromethane, 0.32 mL (2.309 mmol) trifluorcacetic anhydride were added dropwise under ice-bath cooling. The reaction mixture was stirred for 3 h at room temperature.

Afterwards the mixture was concentrated in vacuo and was dried in high vacuum. The oily residue crystallized from petroleum ether, and the product was collected by filtration to yield 0.604 g (yield of theory: 94%) of the 5—(l—(dimethylamino)-4,4,4-trifluoro~3—oxobut—1—en-2— yl)isoxazole derivative. Result of LC/MS : 420.9; 1H NMR (DMSO- d5; CC14): 2.63 (3H, s, N~CH3), 3.40 (3H, s, N—CH3), 3,59 (3H, s, CH3), .46 (1H, dd, CPI—arena), 7.51- 7.55 (1H, d, CH—arom.), 7.64-7.66 (1H, d, CH—arom.), 8.12 (1H, s, CH).

Synthesis of methyl 3—(2-chloro-6~fluorophenyl)—5-(1-(3—chlorophenyl)—5n (trifluoromethyl)-lH-pyrazol—4—yl)isoxazole—4-carboxylate dry f + A J\ N c: N’NH2 H |\ 2 h reflux To a solution of 0.5047g (1.1994 mmol) methyl 3-(2—chloro—6—fluorophenyl)—5-(1- hylarnino)-4,4,4—trifluoro—3~0x0but-1—en~2~yl)isoxazole-4~carboxylate in dry ethanol, 0.1790g (0.9995 mmol) 3—Chloropheny1hydrazine and 0.17 mL (0.9995 mmol) N,N— Diisopropylethylamine (DIPEA) were added. The reaction mixture was heated under reflux for 2 h. The product was ed by using column tography (Petroleum ether:Diethyl ether 80:20), and 0.305 g (yield of theory: 61%) of the pyrazolyluisoxazole derivative were obtained. Result of LC/MS [MiH}+: 499.9; 1H NMR (DMSO- d6; CC14): 3.66 (3H, s, CH3), 7.45-7.50 (1H, dd, CIT-aroma), 7.55—7.58 (1H, d, CH~arom.), 7.65-7.77 (1H, d, CH—arom.), 7.65»7.77 (1H, dd, CH-arom. phenylhydrazine), 7.65-7.77 (1H, d, CH-arorn. phenylhydrazine), 7.85 (1H, s, CH—arom phenylhydrazine), 8,56 (1H, s, 1—pyrazole) Synthesis of (E)(Z-chlorowé-fluorophenyl)~5«(2-(dimethylamino)vinyl)isoxazole~4— carbonitrile F .«J- /N—<:__ dry e O W \N/ 7 h reflux CI Bredereck’s To a solution of 1.5 g (6,3389 mmol) hloro—6—fluorophenyl)—5—methylisoxazole—4— carbonitrile in 100 mL dry toluene, 2.10 g (12.6779 mmol) tert-Butoxy— bis(dimethylamino)methane (Bredereck’s reagent) were added. The reaction mixture was heated under reflux for 12 h. The mixture was concentrated in vacuo and was dried in high vacuum. Petroleum ether was added to the crude material to trigger crystallization of the product. The product was collected by filtration, and 1.791 g (yield of theory: 95.9%) of the Vinyl isoxazol derivative were obtained. Result of LC/MS MH+2 292.0; 1H NMR (DMSO- d6; C(34): 2.93 (3H, s, N-CH3), 3.17 (3H, s, N-CHg), 5.15—5.20 (1H, d, C2112), 7.74—7.78 (1H, d CzHg), 7.45—7.52 (1H, dd, m.), .59 (II-I, d, Gil—atom), 76547.71 (1H, (1, CH- arom.) Synthesis of (Z)-3e(2-chi0ro—6-fluorophenyl)~5—(l~(dimethylamino)~4,4,4-trifluoron3— oxobut—1-en—2-yl)isoxazolecarbonitrile To a solution of 0.5 g (1.714 mmol) (E)-3~(2—chlorow6—fluorophenyl)—5-(2— (dimethylamino)vinyl)isoxazole—4—carbonitrile in 20 mL dry dichloromethane, 0.36 mL (2.571 mmol) trifluoroacetic anhydride were added dropwise under ice—bath cooling. The reaction mixture was stirred for 2 h at r.t.. Afterwards the mixture was concentrated in vacuo and was dried in high vacuum. Petroleum ether was added to the crude material to trigger crystallization of the product, which was collected by filtration to obtain 0.625 g (yield of theory: 94%) of the 5~(1-(dimethylamino)—4,4,4-trifluoro-3—oxobut-1~en—2—yl)isoxazole derivative. Result of LC/MS MHJ“: 388.0; 1H NMR (DMSO-d5; CCl4): 2,75 (3H, s, N—CH3), 3.46 (3H, s, , 7.53—7.59 (1H, dd, CH—arom.), 7—64-76? (1H, d, CH—arom.), 7.73-7.81 (1H, d, (EH-mom), 8.23 (1H, s, CH) Synthesis of hI0ro~6—fluor0phenyl)~S—(l—(3-chlorophenyi)—5-(trifluoromethyl)-1H» pyrazol—4—yl)isoxazole—4-carbonitrile N c: N\ N O /L k dry ethanol N + + N \ Cl N‘NH2 No F F H K 3h reflux F F FF Cl CI To a solution of 0.1 g (0.2579 mmol) (2—chloro—6—fluorophenyl)-5—(l—(dimethylamino)— 4,4,4—trifluoro—3—oxobut—1—en—2—yl)isoxazole-4~carbonitrile in dry ethanol, 0.0462 g (0257911111101) 3—Chlorophenylhydrazine and 0.78 mL (0.2579 mmol) DIPEA were added.

The reaction mixture was heated under reflux for 3 h. The mixture was concentrated in vacuo and was dried in high vacuum. Purification was achieved by using pTLC, and 0.0037 g (yield of theory: 3.0%) of the pyrazolyl—isoxazole tivewere ed. Result of LC/MS MH+: 466.9; 1H NMR (DMSO- d6; C(34): 7.73-7.97 (6H, m, (SH-arena), 8.04 (1H, s, CH—arorn.), 8.8] (1H, s, CH~pyraz.) sis of hloro—G-fluorophenyl)~5-(1-(3-chlorophenyl)—5-(trifluoromethyl)—1H- pyrazol—4-yl)—4—(1H—tetrazol-S-yl)isoxazole (example 3) N3Na NH4C| To a solution of 0.115 g (0.246 mmol) cyano-isoxazole in l0 mL dry DMF, 0.080g (1.231 rnrnol) sodium azide and 0,065 g (1.231 mmol) ammoniunichloride were added. The e was stirred 4 hours at 90°C. The e was ed, and the filter cake was washed with acetonitrile. The filtrate was evaporated in vacuo. The brown, oily residue was purified by pTLC (petroleum etherzethylacetate 80:20 + 5 % acetic acid) and dried in vacuum to yield 49 mg (61%) of example 3. Result of LC/MS MH+: 509,71; 1H NMR (DMSO-d6; CC14): 7.42—7.48 (1H, t, CH—arom‘), 7.51-7.534 (1H, d, (EH-atom), 7.63-7.55 (411, in, CH-arom), 7.81 (1H, s, CHmarom.), 8.58 (1H, s CH—pyraz.) Examples 1 and 2 were synthesized in analogy.

Synthesis of 3-(2-chlor0—6-fluorophenyl)-5—(1n(3-chlorophenyl)—5“(trifluoromethyly1H- pyrazol—4-yl)~4~(thiazol—2-yl)is0xazole (exampleF5) F F c: No 8' f 31o N~o / NaOH /N” / /5N” NH4CI r/ / NQ EtOH HBTU F0 ~N’ DIPEA F9 NH2 F \/0 F C' c; F F c: Cl F . NeO \[ACI Lawessons reagent 1, CI .’ ————Wa- / ____..______._._.. / / N ,N n“ “‘N FS \ NH2 SHWN 7.13g (13.86 mmol) of the ethyl ester were dissolved in 150 mL ethanol, and 10 mL NaOH (2.0 mmol) were added. The mixture was heated under reflux for 1 hour. The ethanol was evaporated in vacuum and the basic solution was adjusted to pH 2 by adding hloride acid (10% aq). The acidic solution was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was d in vacuo and the residue was dried in vacuum to yield 6.0 g (89%) of the corresponding carboxylic acid.

To a solution of 6.0 g (12.34 mmol) of the carboxylic acid and 1.98 g (37.021 mmol) ammoniumchlorid in 20 mL dry DMA, 9.36 g (24.68] mmol) HBTU and 6.45 mL (37.021 mmol) DIPEA were added. The mixture was stirred 3 hours at r.t.. Ethyl acetate was added to the reaction mixture, and it was washed twice with sodium hydrogen ate (5%, aq) and citric acid (5%, aq). The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The oily residue became solid by drying in vacuum. The solid was washed with petroleum ether, ed and dried in vacuum to yield .37 g (90%) of the ponding carboxamide.

To a solution of 5.355 g (11.036 mmol) of the oarboxamide in 20 mL dry dioxane, 4.463 (11.036 mmol) Lawesson's Reagent were added. The mixture was stirred for 4 hours under reflux. Then the solvent was removed in vacuo. The 0in residue was purified by column chromatography (petroleum etherzethylacetate 80:20) to yield 1.716 g (31%) of the respective earbethioamide.

To a solution of 1.022 g (2.039 mmol) of the hioamide in 20 mL dry DMF, 0.5 mL (4.077 mmol) 1,2—Dichlor0ethyl ethyl ether were added. The e was stirred 2 hours at 90°C and then 2 hours at 130°C. The solvent was d in vacuo, and the oily residue purified by column chromatography (petroleum etherzethyacetate 80:20) to yield 180 mg. (17%) of example 5. Result of LCXMS MH+z 524,9; IH NMR (DMSO-d5; CCl4): 6 7.41-7.53 (1H, t, m.), 7.58—7.60 (1H, d CH—arom.),7.65—7.66 (1H, d, CH-—arom,) 7.65-7.67 (1H, d, eal), 7.71-7.73 (1H, t, CH-arom.), 7.74-7.75 (1H, d CH—arom.), 7.74—7.75 (1H, s, CH—thiaz.), 7.83 (1H, s, CH-arom), 7.84—7.85 (1H, s,CH—thiaz.), 7.59 (1H, s, CH—pyraz.) An ative route was realized for examples 29 and 30, exemplarily shown for 29: NH4CI. HOBt Lawesson's reagent ——-w.....~..m....—__._-.

EDCi, NMM 3 —(2—chloro—6-fluor0phenyl)(1 —(2~chlorophenyl)—5—(trifluoromethyl)-1H—pyrazol—4— yl)is0xazole-4—carbexylie acid (100 mg, 0.21 mmol), ammonium chloride (10 mg, 0.21 mmol), HOBt ( 27.8 mg, 0.21 mmol) and EDCI (38.3 mg, 0.25 mmol) were dissolved in 2 mL dry DMF. N—Methylmorpholine (104.2 uL, 2.1 mmol) was added and the reaction was stirred at room temperature for 72 h. DMF was d by evaporation. An aqueous solution of aqeous 5% citric acid was added. The precipitate was filtered and dried. The mixture was purified by pTLC (CH2C12/MeOH 95/5) to give 50 mg (yield 50 %) of the respective carboxamide.

The Lawesson’s reagent step was performed as described within the synthesis of example 5.

WO 01263 To a solution of 3~(2—chloro-6—fluorophenyl)—5-(1~(2-chlorophenyi)(trifluoromethyl)~1H— pyrazol—4—yl)isoxazole—4-carbothioamide (15 mg, 0.03 mmol) in 0.5 mL ethanol was added 2- acetaldehyde (0.046 mL, 0.4 mmol). The mixture was stirred for 48 h at 85°C. The mixture was concentrated, diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting oil purified by pTLC (DCM : MeOI—l 100:5) to give 10.4 mg of example 29 as a yellow oil (yield 66%). Result of LC/MS MH+: ; 1H NMR ): 8 7,11 (m, 1H), 7,28 (m, 1H), 7,33- 7,42 (m, 6H), 7,52 (m , 1H), 8,37 (s, 1H) Synthesis of methyl 3—(2—chloro-6—fluorophenyl)—5-(1~(2,4-difluorophenyl) (trifluoromethyl)-IH-pyrazolntl-ylfisoxazole—4-carboxylate (example 4) 3—(2—chlorofluorophenyl)~5—(1-(3—chlorophenyl)—5—(trifluoromethyl)—1H-pyrazolyl) ‘ isoxazole—4—carbothioamide (50.0 mg, 0.100 mmol) and Chloroacetone (0.04 mL 0.5 mmol) were dissolved in 10 mL dry ethanol. The mixture was stirred at r.t. for 4 h. Purification of product was achieved by pTLC (petroleum ether:ethyl acetate 80:20). Drying in high vacuum yielded 20 mg (3 7%) of example 4 as a colorless oil. Result of LC/MS MH+: 53 8,76 1H NMR (DMSO-ds; CCl4): 2.32 (s, 1H, CH3), 6.72 (s, 1H, CH—thiaz.), 7.04-7.52 (m,7H, atom), 8.33 (s, 1H, CH—pyraz.); Synthesis of 4—bro1110—3-(2-chloro-6—fluorophenyl)(1-(3-‘fluorophenyl)-5~ (trifluoromethyl)-1Hupyrazol-éE-ylfisoxazole 0.32 g (0.70 mmol) of the carboxylic acid were dissolved in aq. NaOH solution (20 mL water + 0.115 g NaOH). e (0.34 g, 2.1 mmol) was added slowly and dropwise to this on at stirring and cooling (06°C). Stirring continued for 2 hours at 06°C and for 2 days at r.t. The precipitate was filtered off and ded in 5% aq. NaOH solution (10 mL). After 2 hours of stirring solids were filtered off, washed with water and dried in vacuum to yield 0.15 g (0.30 mmol, 42%) of the brominated isoxazole as white crystals. Result of LC/MS MH+: 505.7; 1H NMR (DMSO—ds; CC14): 7.35 — 7.48 (In, 4 H) 7.52 (d, #828 Hz, 1 H) 7.61 - 7.74 (In, 2 H) 8.4 (s, 1 H) Synthesis of methyl 3-(2-chloro—6—fluorophenyl)—5-(I-(3-fluor0phenyl)—5- (trifluoromethyl)—1H—pyrazol—4—yl)isothiazole—4-carboxylate (example 7) A solution of 102 mg (0.217 mmol) of the carboxylic acid in 8 mL SOC12 was refluxed for 3 h. Volatiles were evaporated in vacuum thoroughly. The residue was dissolved in 8 mL absolute dioxane and added dropwise to a stirred mixture of 825 mg N2H4*H20 and 6 mL absolute dioxane. Volatiles were evaporated, some water was added to precipitate an oily pink solid. Water was removed, residue was washed with water, then d with 5 mL water with 10 drops of AcOH and finally washed with water. The product was partially ted by boiling heptane (38 mg) and lly extracted by ether with further treating of ethereal solution by e (39 mg). The hydrazide was attained in a total yield of 77 mg (73%).

A solution of the hydrazide (125 mg, 0.258 mmol) in 2.0 mL methyl orthoether was heated to boiling temperature and immediately cooled to r.t. Further additional 2 mL of methyl orthoether was added and the solution was d for 1.5 days. Excess orthoether was evaporated, the residue was treated with boiling e and evaporated. The residue was purified by column chromatography on silica gel (eluent EtOAc/heptane 1/3 to 1/1), the fraction with pure product was ed and evaporated to give 47 mg (3 7%) of example 7.

Result of LC/MS hill-1+: 494.8; 1H NMR (DMSO—dé; CCl4): 7.20 (td, 3:853, 0.75 Hz, 1 H) 7.24 « 7.44 (m, 5 H) 7.47 — 7.59 (111,2 H) 8.35 (s, 1 H) 8.40 (s, 1 H). sis of hloro—6—fluorophenyl)—5-(l-(3—chlorophenyI)(trifluoromethyl)—1H- pyrazolyl)—4-(oxazol—S~yl)isoxazole (example 8) HBTU To a solution of 10.8 g (22.2 mmol) of the carboxylic acid, 2.17 g (leq) N,O— Dimethylhydroxylamine and 8.42 g (leq) HBTU in DMF, 3.68 mL DIPEA were added. The mixture was stirred overnight at r.t. The solvent was removed in vacuum. The residue was dissolved in ethyl acetate and extracted with sodium hydrogen carbonate (5%, aq) and citric acid (5%, aq). The organic layer was dried over anhydrous magnesium e and the solvent was removed in vacuum. The product was isolated by column chromatoghraphy (6:4 petroleum etherzethyl acetate). The product resulting Weinreb amide was dried under vacuum to yield 2.28 g (19%).

To an oled solution of 1.0 g (1,8895 mmol) of the b amide in dry THF 0.95 mL (0.5 eq 3 2 eq H) lithiumaluminium hydride were added. After stirring for 30 min, TLC (4:1 petroleum ethyl acetate) shows no more educt. To quench the ing lithiumaluminium hydride, ice was added carefully to the mixture. For further purification, the solution was diluted with ethyl acetate and extracted three times with sodium hydrogen carbonate (5%, aq) and citric acid (5%, aq). The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed in vacuum. The resulting aldehyde was dried under vacuum to yield 520 mg (58%).

To a solution of 0.5 g (1.0634 mmol) the aldehyde in dry methanol (10 mL), 5 mL sodium olate (from 83 mg sodium in 5 mL dry methanol) were added lly under argon.

After stirring for 5 min at r.t., 0.25 g (1.2eq) TosMIC were added stepwise. The mixture was stirred under reflux for 2 hours. The product of example 8 was isolated by preparative HPLC/MS to yield 128mg (24%). Result ofLC/MS MH+2 508.78 1H NMR (DMSO—d5; CCl4): 6.92 (1H, s, CH-oxazole), 7.49~7.78 (6H, m, CH—arom.), 7.87 (II-I, s, CH~arorn.), 8.41 (1H, s, CH—oxazole.), 8.50 (11-1, 8, CH—pyraz.) An alternative route was realized for examples 28, 32 and 33, arily shown for 28: 3 —(2—chloro-6—fluorophenyl)(1 —(2-fluorophenyl)-5—(t1ifluoromethyl) — 1 H-pyrazol-4— yl)isoxazole—4-carboxylic acid (0.3 g,' 0.64 mmol), N,O—Dimethylhydroxylamine (0.062 g, 0.64 mmol), HOBt (0.082g, 0.064 mmol) and EDCI (0. 118 g, 0.76 mmol) were dissolved in 3 mL dry DMF. N—Methylmorpholine (104 llL, 6.4 11111101) was added and the reaction was stirred at room temperature overnight. DMF was d by evaporation. An aqueous solution of 5% citric acid was added. The precipitate was filtered and dried. The t purified by pTLC (PE/EB 7/3) to give the Weinreb amideas an orange solid (149 mg, yield 45%). The uent steps were performed as described for the synthesis of example 8.

Within the final step of this synthetic route in similar conversions, byproduct formation ed in a few cases resulting from a replacement of the aromatic fluoro substituent by methanolate, giving rise to examples 31 and 34.

Synthesis of 2—(3~(2-chlorofluorophenyl)—5~(1—(3-fiuor0phenyl)(trifluoromethyl)- lH—pyrazolyl)isoxazol—4-yl)thiazol~4—ol (example 9) A mixture of 0.145g (00311111101) of the above thioamide, 0.60g (04211111101) bromoacetic acid and SmL toluene was heated under reflux for 2h. Then reaction mixture was evaporated in vacuum. Thick oil was washed with water and purified by column chromatography on silica gel, using CC14, then CHClg/CC14 (1:1, V/v) as eluents. Yield of glassy nce of example 9 is 0.063g (40%). Result of LC/MS MH+2 ; IH NMR (DMSO—dg; CCl4): 7.60— 7.94 (7H, m, CH—arom.), 8.62 (1H, s, CH—pyraz.), 8.84 (1H, s, CH-thiazole), 10.81 (1H, s, Synthesis of 3-(2-chlorofluorophenyl)—5-(1-—(3-fluorophenyl)—5-(trifluoromethyl)—1H- pyrazol—4-yl)—4—(4-methoxythiazol—Z-yl)isoxazole (example 10) NaOH F H20 CH3I N N' RY F To a stirred solution of 52 mg (0.1 mmol) hydroxyl thiazole (example 9) in 5 ml dioxane were added alternately in small portions 0.140 g (1.0 mmol) of CH31 and a solution of 40 (1.0 mmol) NaOH in 1 1nL water. The pH has to be kept at 8-9 and the temperature at 40- 50°C. Then the reaction mixture was d for 1 hour at 4050 0C, diluted with 15 mL water, neutralized with HCl to pH 6-7. Thick oil was extracted with CCl4, dried with MgSO4 and purified by column chromatography on silica gel, using CCI4, then CHC13 / CC14 (1:1, v/v) as eluents. Yield of glassy nce of example 10 is 20 mg (37%). Result of LC/MS MH+: 539.03; 1H NMR (DMSO'dG; CC14): 3.73 (3H, s, CH3), 6.59(1H, s, CH—thiazole), 7.52— 7.78 (7H, m, CH—arom.), 8.62 (1H, s, az.) Synthesis of 2-(3-(Z—chloro-6—fluorophenyl)(1-(2~fluorophenyl)—5—(trifluoromethyl)— IH-pyrazol—4-yl)isoxazol—4-yl)methyl-1,3,4—oxadiazole le 11) Cl Cl CI F F F /N~O O 0 Na F F o F F / FLO F / A k O / "WWW—3' / / ——~———- F F N / —.. ,N O \N' S FN/ (N H|\;I O N MN h.

F O N NH2 F OiNH NX F A solution of 3-(2—chloro—6»fluor0phenyl)—5-[1~(2—fluorophenyl)—5—(trifluoromethy1)-1H— pyrazol—4—yl]isoxazole—4—carbohyclrazide (66 mg, 0.137 mmol) in acetic anhydride (3.5 g) was kept in a sealed tube at 140°C for 18 hours. The solvent was removed in vacuum. Residue was re—evaporated with ethanol, and treated with boiling heptane. The concentration and cooling of heptane extract gave a solid. Column chromatography on silica gel (eluent eptane, 1/ 1) gave 40 mg (58%) of colorless powder of example 11. Result of LC/MS MI—H: 508.05 1H NMR (400 MHz, METHANOL—d4) 5 ppm 2.44 (s, 3 H) 7.28 - 7.35 (m, 1 H) 7.41 - 7.49 (111.3 H) 7.69 (s, 3 H) 8.48 (d, J=0.50 Hz, 1 H) atively, the reaction can be performed under microwave irradiation as realized for examples 4, 10, 18, 19 and 26, exemplarily shown for 4.

F0 '7“ \v’N A similar mixture as generated within the synthesis of example 11, consisting of hydrazide in acetic anhydride, was heated under microwave irradiation at 140°C for 6 h. The mixture was diluted with dichloromethane and washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was purified by pTLC (EB/PE 1 :1).

Synthesis of N—(3-(4-(3-(2—chloro—6-fluorophenyl)—4m(5—methyl-1,3,4-0xadiazol yl)isoxazol—S-—yl)—5-(trifluoromethyl)-1H—pyrazolyl)phenyl)acetamide (example 11) 0 j :4ka —(1—(3—acetamidophenyl)-5~(trif1uoromethyl)—lH-pyrazol—4—yl)(2—chloro-6—fluorophenyl) isoxazole—4-carboxylic acid (100 mg, 0.196 mmol), acethydrazide (16.0 mg, 0.216 mmol) and HATU (97.1 mg, 0.255 mmol) were dissolved in THF (2.00 mL). DIPEA (268 uL, 0.589 mmol) was added and the resulting e was d at r.t. for 3.5 11. Additional acethydrazide (160 mg) and HATU (100 mg) were added and stirring was continued at lit. for 19 h. The reaction mixture was diluted with CH2C12 (40 mL) and washed with 1N aq. HCl (1 X 20 mL) and water (2 X 20 mL). The combined aqueous layers were re—extracted with (31-12(312 (20 mL) and the ed organic layers were dried over NazSO4 and concentrated in vacuo. The e was purified by pTLC (EtOAc/MeOH 2 9:1) to give 34 mg of the intermediate as brown oil (yield 31 %). 2012/051360 The intermediate N—(3 —(4~(4—(2~acetylhydrazinecarbeny1)—3—(2-chlorofluorophenyl) isoxazoin5—y1)—5—(trifluoromethyl)—1H—pyrazol—l-yl)phenyi)acetamide (25.0 mg, 0.044 mmol) was dissolved in acetic acid (1.50 mL). Acetic anhydride (104 uL, 1.1 mmol) was added and the reaction mixture was heated in the microwave to 140 °C for 8 h.The reaction mixture was diluted with water (40 mL) and extracted with CH2C12 (3 x 20 mL). The combined organic layers were washed with water (10 mL), dried over Na2804 and concentrated in vacuo.

The residue was purified by pTLC (CH2C12/MeOI-I 3 9:1) to give 2.6 mg of example 11 as a yellow solid (yield 8%). Result of LC/MS MH+2 546,87; 1H NMR MeOD): 5 ppm: 2,05 (s, 3H), 2,33 (s, 311), 7,20 (m, 2H), 7,33-7,61 (m, 4H), 7,93 (s, 1H), 8,39 (s, 1H) Synthesis of 3—(2-chlor0flu0rophenyl)—4-(5—methyl—1,3,4-thjadiazolyl)-S-(l-(pyridin- 4—yl)—5-(trifluor0methyl)-1H~pyrazolyl)isoxazole (example 22) / N N o o F F l AOJK CI 1 N‘"O / \‘ \ f / / {Q’QN on’s reagent —————————-—4 1' ———————b F0 I}|H To a solution of 3-(2-chloro—6-fluorophenyl)—5~(1-(pyridinn4—yl)—5—(triflueromethy1)—1H- pyrazolyl)isoxazole~4~carbohydrazide (0.03 g, 0.06 mmol) in acetic acid (0.03 mL) was added acetic anhydride (0.01 mL, 0.06 mmoi). The mixture was stirred at r.t. for 2 h. The mixture was diluted with dichloromethane and washed with water, dried over sodium sulfate, filtered and concentrated under d pressure to give 29 mg of the intermediate as a brown oil.

To a on of N'—acetyl~3~(2~chloro-6—fluorophenyl)—5—(1—(pyridin—4—yl)~5~(trifluoromethy1) —1H—pyrazol~4~yl)isoxazole~4-carbohydrazide (0.029 mg, 0.01 mmol) in dioxane (1.5 mL) was added Lawesson‘s Reagent (23.1 mg, 0.01 mmol). The e was stirred at reflux for min. The mixture was then diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure.

The product was purified by pTLC (CH2C122MeOl-I 100:5) to give 7.7 mg of example 22 as an oil (yield 26%). Result of LC/MS MH+: ; IH NMR (CDCig): 5 ppm: 2,27 (s, 3H), 7,18 (m, 1H), 7,30 (d, 111), 7,36 (m, 2H), 7,57 (m, 1H), 8,00 (s, 1H), 8,41 (d, 1H), 8,58 (d, 1H) Examples 20, 21, 23, 27, and 3 were sized in analogy to example 22. 2012/051360 sis of N-(3-(4-(3-(2—chloro-fi-flnorophenyl)(S-methyl-1,3,4—thiadiazol-2— xazolu5‘y1)-5—(trifluoromethyl)—1H-pyrazol—1~yl)phenyl)acetamide (example 12) “0 ”to / Lawesson's reagent Treatment of N—(3—(4~(4-(2-acetylhydrazinecarbonyl)—3-(2—chloro—6—fluorophenyl)isoxazol-5— yl)—5—(trifluoromethyl)—1H—pyrazol-1—yl)phenyl)acetarnide with Lawesson’s reagent according to the procedure described for example 22 resulted in the formation of the thiadiazole but simultaneously in the formation of a thioamide at the aryl substituent at the pyrazol ring. For a re—generation of the acetylamino substituent, N—(3—(4-(3—(2~chloro—6-fluorophenyl)-4—(5- methyl-1,3,4-thiadiazol—2-yl)isoxazol—S—yl)(trifluoromethyl)—1H—pyrazol yi)phenyl)ethanethioamide (19.0 mg, 0.032 mmoi) was dissolved in CH2C12 (2.0 mL). 3— Chloroperoxybenzoic acid (70%, 16.2 mg, 0.065 mmol) was added and the resulting mixture was stirred at It for 1 h. The reaction mixture was diluted with sat. Na2803 (10 mL) and stirred vigorously for 10 min. Satd NaI-IC03 (10 mL) was then added and the mixture extracted with CH2C12 (3 X 15 mL). The combined organic layers were washed with ted Nal-ICO3 (10 mL), dried over Na2804 and concentrated in vacuo.

The residue was purified by pTLC (CHZClg/MeOH x 95:5) to give 10.2 mg of a yellow solid (yield 37 0/o). Result of LC/MS MH+: 562,75; 1H NMR (CDCIg): 5 ppm: 2,10 (s, 3H), 2,62 (s, 3H), 7,11 (t, 1H), 7,33 (d, 1H), 7,35-7,48 (m, 2H), 7,65 (m, 3H), 8,21 (s, 1H) Synthesis of hlorofluor0phenyl)(1—(2—fluorophenyl)-5—(trifluoromethyl)-1H— Iyl)F4—(5--methyl--1 ,34-thiadiazol——2—yl)isoxazole (example 12) 31-O HBTU. DIPEA Lawesson‘s reagent hi} 8 N / FZNF/Qfl/ W Ci \‘N F0 OH HZNfi 3.44 g (7.3 mmol) of hloro-6—fluoropheny1)—5—(1—(2—fiu0r0phenyl)—5—(trifluoromethy1)— 1H~pyrazo1—4—yl)isoxazole—4-carboxylic acid were dissolved in 19 ml of DMF. 2.92 g (7.7 mmol) of HBTU and 6.06 mi (36.65 mmoi) of DIPEA were added at r.t.. Alter 20 min. stirring at r.t., 1.63 g (22 mmol) of acethydrazine were added and the mixture was stirred at r.t. overnight. The mixture was diluted with ethyl acetate (60 ml) and washed with 60 ml water. The aqueous layer was re-extracted with EB and the combined organic layers were 2012/051360 dried over MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was purified Via pTLC (CHZClz/MeOH 95/5) to give 1.3 g of the intermediate as an orange solid (yield 34%). The thiadiazole ion out of the intermediate was achieved using Lawesson’s reagent according to the procedure described for example 22.

Synthesis of 3—(2-ehlorofluorophenyI)—5—(l—(3-.chlorophenyl)-S-(trifluoromethyl)—lI-I- pyrazol—4-y1)(1,3,4-thiadiazoI—2—yl)isoxazole (example 8) F 1i) F i H OH NO / FF:© Lawessons reagent OHNWONH 3 —(2~chloro—6ufluorophenyl)—5—( 1 —(3 -chlorophenyl)—5—(trifluoromethy1)—1H—pyrazol y1)isoxazolecarbohydrazide (85 mg, 0.2 mmol) was treated with formic acid (6.4 uL, 0.2 mmol). The mixture was stirred at r.t. for 72 h. To the reaction mixture was added water, the resulting itate was collected, washed with water and dried in vacuum to give 61 mg of the ediate as a colorless solid. To a solution of the intermediate 3—(2—chloro—6- henyl)~5-—(1 —(3 ~chlorophenyl)—5—(trifluororn ethy1)— lH—pyrazol—4—yl)—N'~ formylisoxazole—4—carbohydrazide (20 mg, 0.038 mmol) in dioxane (2 mL) was added Lawesson‘s Reagent (0.033 mL, 0.1 mmol). The mixture was stirred at reflux for 3 11. The mixture was diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and trated under reduced pressure. The product was purified by pTLC (EB/PE 1:1) to give 6 mg of example 8 as a colorless solid (yield 31 %). Result of LC/MS MH+2 525,72; 1H NMR (MeOD): 5 7,35 (t, 1H), 7,49 (d, 1H), 7,59—7,71 (m, 5H), 8,37 (s, 1H), 9,38 (s, 1H) Synthesis of 3-(2-chlorofluorophenyl)—5~(l—(3-fluorophenyl)-5—(trifluoromethyl)-—1H- pyrazolyI)(furanyl)isoxazole (example 13) The tube was charged with 4—bromo—3-(2—chloro-6—fluorophenyl)«5—(1—(3-fluoropheny1)-5~ (trifluoromethyl)-lH—pyrazol—4—yl)isoxazole (30 mg, 0.06 mmol), is(triphenylphosphine)palladium(0) (0.010 g), 1.5 mL 1,2—Dimethoxyethane and was purged with argon. Then furan—3-yiboronic acid (0.012 g, 0.1 11111101) and an aqueous solution of cesium carbonate (0.05 g in 0.2 mL) were added. The reaction mixture was heated under microwave irradiation to 100°C for 2h. The solvent was evaporated and the product was isolated by column chromatography (hexane : ethyl e 25 : 1) to obtain 5 mg (17%) of a yellowish solid of example 13. As a major side reaction, hydrodebromination was observed.

Result of LC/MS MH-E-z 492.05; 1H NMR (CDClg; CC14): 6.18 (1H, m, CH~furyl), 7.12— 7.53 (9H, m, CHmaromfi CH—furyl), 7.91 (1H, s, CH—pyraz.) Example 17 was prepared in y to e 13.

A similar procedure was applied to the sis of examples 14, 6, 7, 9, and 24, only replacing tetrakis(triphenylphoSphine)palladium(0) by dichlorobis(triphenylphosphine) palladium (for example 14), and for examples 6, 7, 9 and 24 by also ing an aqueous solution of cesium carbonate by an aqueous solution of sodium carbonate.

Synthesis of 3—(2-chlorofluorophenyl)—5-(1—(3—fluor0phenyI)(trifluoromethyl)-1H- pyrazol—4-yI)-4—(thiopheny])isoxazole (example 16) A microwave tube was charged with oisoxazole (0.03 g, 0.06 mmol), Pd(PPh;)ClZ (0.003 g), DME (1.5 mL) and purged with argon. Then 3uthienylboronic acid (0.014 g, 0.1 mmol) and an aqueous solution of CszC03 (0.05 g in 0.2 mL) were added. The reaction mixture was heated under microwave irradiation to 100°C for 1.5 h. The solvent was evaporated and the resulting e was separated by column chromatography (hexane, hexane:EtOAc 50:1, hexanezEtOAc 25:1) to give 0.010 g of the d product. (yield 33%).; 1H NMR (CDClg): 6,85 (1H, m, CH—thienyl), 7,04 (1H, m, CH-thienyl), 7,11 (1H, m, CH~ar0m.), 7,24—354 (7H, m, CH—arom.+CH—thienyl), 7,80 (111, s, CH—pyraz).

Synthesis of 2-(3-(2-chloro-6wfluorophenyl)u5-(1—(2-fluor0phenyl)—5-(trifluoromethyl)— azol-d—ylfisoxazol—4-yl)—1,3,4—0xadiazole (example 15) A solution of 3—(2—chloro—6—fluorophenyl)—5—(l—(2—fluorophenyl)—5—(trifluoromethy1)—1H- pyrazol-4~yl)isoxazole—4—carbohydrazide (0.076 g, 0.157 mmol) in 4 g trimethyl orthoformate was kept in a sealed tube at 125°C for 3 days. The solution was evaporated to dryness and the residue was crystallized from heptane to give 36 mg (46%) of a ish solid of example . Result of LC/MS MH~1~: 493.75; 1H NMR (methanol-d4; 400 MHZ) 5 ppm: 7.30—7.35 (1H, m, CH-arom.), 7.42—7.48 (3H, m, CH—arom.), 7.60—7.70 (3H, m, CH—arom.), 8.51 (1H, s, CH- oxadiazole), 8.93 (1H, s, CH—pyraz.) A t of this procedure was used for the synthesis of examples 5, 13, 14, 15, 16, 17, and 25, exemplarily shown for 5: The aforementioned mixture of hydrazide and trimethyl orthoformate (cf. synthesis of example 15) was heated under microwave irradiation to 125°C for 8 h. The mixture was diluted with dichloromethane and washed with water (3 x), dried over sodium e, filtered and concentrated under reduced pressure. The product was d by pTLC EE/PE 1:1 to give 6 mg of example 5 as white solid (yield 24 %).

Synthesis of methyl and ethyl 2—{3-(2-chloro-6~fluorophenyl)[1—(3-fluorophenyl)- -(trifluoromethyl)-1H—pyrazolyl]isoxazol-4—yl}-1,3-thiazolecarboxylate (examples 1 and 2) 1 ) N OH*Ha OH SOCE 2) He: MeOH A mixture of the carbothioamide (0.242 g, 0.5 mmol) and ethyl bromopyruvate (0.118 g, 0.6 mmol) was heated under reflux for 3 h in 2 ml of dry e. The on mixture was cooled to room temperature and diluted with 20 ml of water. The resulting oil was separated by decantation, dissolved in CC14, dried with MgSOi. The compound was purified by column chromatography using silica gel and CCl4, then CHClg as eluents to give 0.17 g of example 1 as an oil (yield 59%). 1H NMR (DMSO-dg, 400 MHZ): 5 8.76 (1H, s, Hflfiasgle), 8.50 (1H, s, prmsnle), 7.80.753 (7H, m, Harm“), 4.28 (2H, q, 127.3 Hz, CH2), 1.27 (3H, t, J=7.3 Hz, Me).

Transesterificafion of example 1 into e 2 was achieved as s: To a boiling solution of 0.118 g (0.2 mmol) of the ethyl ester in 5 ml ethanol was added a solution of 0.08 g (2 mmol) NaOH in 0.5 ml water. The reaction mixture was heated to reflux for 10 min, then cooled to room temperature, diluted with water acidified to pH 3—4 and concentrated to a volume of 1 ml. The acid was extracted with 10 ml CH2C12 and dried over MgSO4. To the solution were added 0.1 ml (1.4 mmol) SOClz, and the mixture was heated under reflux for 1 h. The mixture was evaporated in vacuum. The e was taken up in 2 ml of dry methanol and was heated under reflux for 20 min. Then the mixture was concentrated in vacuum and diluted with 10 m1 of water. The product was extracted with 10 ml CH2C12 and dried over MgSO4. The solution was ated in vacuum to give example 2 as a glassy solid (0.063 g, 56 %). IH NMR (DMSO—ds, 400 MHZ): 5 8.72 (1H, s, Hmimle), 8.52 (1H, s, prz-azm), 7.82—7.53 (7H, m, Harem), 3.82 (3H, s, OMe). 2012/051360 Synthesis of 2-{3-(2—Chloro—fi-fluorephenyl)~5—[1-(3-fluor0phenyl)—3-(trifluoromethyl)— 1H—pyrazol—4-yllisoxazol~4-—yl}(trifluoromethyl)-1,3,4—oxadiazole le 6) NH2 0 N.._ | fiN 0 Q F fF MNN F o F F F rim DR 0 ,I \ + C' F;g /< F N OH Q W N “I ,‘N \ N’O 01%F w /N \ F O F F \ N-‘O F N-O A solution of 3-(2—chloro-6—iluorophenyl)~5—[1-(3—fluorophenyl)~3—(trifluoromethyl)—1H~ pyrazoi-4—yl]isoxazole—4-carbohydrazide (158 mg, 0.327 mmol) and trifluoroacetic acid anhydride (342 mg, 1.628 mmol) in 9 g of absolute dioxane was heated under rcfluxe. TLC showed intermediate product which gradually converted into desired 1,3,4—oxadiazole. After heating for 3 days, the mixture was evaporated to dryness The oily residue was extracted with boiling heptane, heptane extracts were combined and evaporated to dryness. Oily residue was purified by column chromatography on silica gel, eluent EtOAc/heptane, 1/2 to yield 18 mg of pure example 6 as a viscous oil (yield 10%). 1H NMR (CDCl3; C014): 5 7,24 (1:, 1H), 7,32 (m, 2H), 7,41 (m 2H), 7,55 (in, 2H), 8,38 (s, Ill) The synthesis of compounds of the Illustrative Examples is described in the following: 1. Synthesis of compounds of formula (I! The compounds of formula (I) were ed h the synthetic route described in scheme (1). Methyl 3-(2~chloro-6—fluorophenyl)-5—methylisoxazolem4~carboxylate was sed from Apollo ific Ltd, Whitefield Rd, Bredbnry, Stockport, Cheshire, SK6 2QR.

Bredereck's reagent (tert—Butoxy—bis(dimethylamino)methane) was purchased from Apollo Scientific Ltd, ield Rd, Bredhury, Stockport, Cheshire, SK6 2QR. Trifluoroacetic anhydride was purchased from Acros Organics BVBA, lanssen Phannaceuticalaan 3a, 2440 Geel, Belgium. 3—Chlorophenylhydrazine hydrochloride was sed from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA.

Synthesis of benzaldoxime derivatives, exemplarily shOWn for 2-chloro—6- fluorobenzaldehyde oxime CI 0 C; N F F To a stirred mixture of 2-chloro—6—fluorobenzaldehyde (5 g, 31.5 mmol), ethanol (10 mL), ice and water (30 mL) and hydroxylamine hydrochloride (2.8 g, 40.3 mmol), an aqueous solution of NaOH (3.6 g, 90 mmol in 5 mL of water) was added. The mixture was stirred for an hour and extracted with 40 mL of ether to remove impurities. The aqueous layer was lized with HCl and extracted with ether (2x50mL). Extracts were dried over Na2804 and evaporated to give 5.19 g of the aldoxime (yield 93%).

Synthesis of ethyl 3—(2—chlor0—6-fluorophenyl)—5-methylisoxazole—4—carboxylate G 0 Raw. —-———------h “~th 0H DMF. HCI 01"! CE CI Ma,EtDH, EtEO To a solution of (E)—2-chloro—6—fluorobenza1dehyde oxime (2 g) in 10 mL Dimethylformamide (DMF) at room temperature 0.23 g rosuccinimide (NCS) were added. Dry en chloride was bubbled into the DMF solution until the reaction ature rise up to 350C. Then 1.21 g N—chloro-succinimide were added in portions, the temperature was kept at 35 — 45°C. The reaction mixture was cooled to room temperature and poured into 30 mL ice and extracted with ether. Combined ts were dried and evaporated to give 2.5 g of 2—chloro—6—fluoro-N-hydroxybenzimidoyl chloride as a yellow oil.

A solution of ethyl sodium acetoacetate [from sodium (0.33 g), dry ethanol (10 mL) and ethyl acetoacetate (1.75 g)] was added slowly to a stirred solution of the hydroxamoyl chloride (2.5 g) in 20 mL ether at 0 — 3°C. The mixture was d to warm to room temperature overnight, and the solvent was evaporated in vacuo. The residue was shaken with water and ether, ether extract was evaporated and the product was purified by column chromatography e) to give 2.2 g of ethyl 3—(2—chloro—6—fluorophenyl)methylisoxazole—4—carb0xylate as a colorless oil. Result of LC/MS [M+H}+r 283.95; 1H NMR (DMSO—dé; CC14): 0.98- .1.03 (3H, t, CH3), 2.77 (3H, s, CH3), 4.05—4.12 (2H, q, CH2), .67 (3H, m, CH—arom.) Synthesis of methyl 3-(2,6—dichlorophenyl)~5-methylisexazole—4-earbexylate O 0 O—d Cl MO/ CP [\1“ i / OH DIPEA \ CI 01 To a solution of 0.1 g (0.4455 mmol) alpha—Chlor0—2,6—diehlorobenzaldoxime in 5 mL methyl 3-0x0butanoate, 0.11 mL (1.5 eq) diisopropylethlamine were added. The mixture was stirred for 24 h then eetate was removed in the vacuo. The e was dried under high vacuo and the crude product was triturated in water until it became solid. The solid was filtered off and further purified by recrystallization from a water-methanol mixture. The crystals were filtered off, washed with water and dried under d re to afford 248 mg (87%) of methyl 3—(2,6-dichlor0phenyl)—5-methylisoxazoie—4-carboxylate. Result of LC/MS [M+H]+: 286.12; 1H NMR (DMSO-dg; CC14): 2.77 (3H, s, CHg-isooxazole), 3.28 (3H, s, CH? methoxy), 7.54—7.65 (3H, m, aromatic) Starting from either unsubstituted benzaldehyde, 4—chiorobenzaldehyde, 2- fluerobenzaldehyde, 2—ch10robenzaldehyde, 2,4-dichlor0benza1dehyde, 4— methoxybenzaldehyde, 3—fiuorobenzaldehyde, 2,6-diehlor0benzaldehyde, 2,4- dichlorobenzaldehyde, 3—flu0r0isonic0tina1dehyde or 3,5—dieh10r0isonie0tina1dehyde and using either methyl or ethyl 3—0X0butanoate, the aforementioned synthetic routes were used to synthesize all differently substituted methyl or ethyl 5—methylm3—phenylisoxazolem4- carboxylate building blocks required for the preparation of the respective examples of this invention, e.g: Ethyl 3-«(2,4—dichlorophenyl)methylisoxazolecarboxylate, oil, yield 82% 1H NMR (DMSO—Dé, CCl4): 1.10 (3H, t, CH3), 2.74 (3H, s, CH3), 4.10 (2H, q, CH2), 7.42 (1H, d, m.), 7.47 (1H dd, CH—arom.), 7.59 (1H, (1, CH- arom.).

Methyl eth0xyphenyl)—5~methylisoxazole-4—carboxylate yield 65% 1H NMR (DCClg); 2.71 (3H, s, CH3), 3.79 (3H, s, OCHg), 3.85 (3H, s, OCH3), 6.97 (211, AB— syst., CH-arom.), 7.60 (2H AB-syst., CPI—arena.) Synthesis of methyl 3—(2-chlorofluorophenyl)(2-(dimethylamjno) vinyl)isoxazole—4- ylate O l \O F O O F r toluene O \ ‘5. / N4<0+ _.—’ I N + \ / \ N\ N~— 6 h reflux cu / CI To a solution of 0.1 g (0.3708 mmol) methyl 3-(2—chloro—6—fluorophenyl)methylisoxazole 4—carboxylate in 10 mL dry toluene, was added 0.15 mL (0.7417 mmol) tert-Butoxy- methylamino)methane. The on mixture was heated under reflux for 6 h.

The mixture was concentrated in vacuo and was dried in high vacuum. Petroleum ether was added to the oily residue and crystalline product developed. The product was collected by ion and 0.070 g (yield of theory: 58%) of clean product were obtained. Result of LC/MS [M+H]+: 325.0; 2H NMR (DMSO-dfi; CC14): 3.02 (6H, s, N-CH3), 3.53 (3H, s, CH3), 5.54- .58 (1H, (1, CH), 7.72-7.76 (1H, (1, CH), .38 (1H, dd, Cit—arena), 7.44-7.47 (1H, d, CH—arorn.), 7.56—7.58 (1H, d, CH—arom.) Synthesis of methyl 3~(2~chlorofluorophenyI)(I-(dimethylamino)—4,4,4-trifluoro—3-— oxobut—l-enyl)isoxazoIe—4—carboxylate 0,—— To a solution of 0.5 g (1.5397 mmol) methyl 3-(2—chloro-6~fluorophenyl)—5—[2- (dimethylamino) Vinyl]isoxazole—4—carboxylate in 20 mL dry dichloromethane, was added dropwise under ice—bath g 0.32 mL (2.309 mmol) trifluoroacetic anhydride. The reaction mixture was d for 3 h at room temperature. Afterwards the mixture was concentrated in vacuo and was dried in the high vacuum. The oily residue crystallized with petroleum ether and the product was collected by filtration to obtain 0.604 g (yield of theory: 94%) of clean product. Result of LC/MS [M+H]+: 420.9; 1H NMR (DMSO~ d6; CCla): 2.63 (3H, s, NHCH3), 3.40 (3H, s, N-CH3), 3,59 (3H, s, CH3), 7.40-7.46 (1H, dd, CH~arom.), 7.51— 7.55 (1H, d, (EH-atom), 7.64—7.66 (1H, d, CH-arom.), 8.12 (1H, s, CH).

Synthesis of methyl 3-(2-chloro-waluorophenyl)(l-(3-chlor0phenyl)—5— (trifluoromethyl)—1H—pyrazolyl)isoxazolecarboxylate (example 1-11) dry ethanol NHZ + ARI/k ..

CI N’ H K 211 reflux To a solution of 0.5047 g (1.1994 mmol) methyl 3—(2-chloro—6-fluorophenyl)(1— (dimethylamino)-4,4,4~trlfluoro—3—oxobut—l—en—2—yl)isoxazolecarboxylate in dry ethanol, were added 0.1790 g (0.9995 mmol) 3-Chlorophenylhydrazine and 0.17 mL (0.9995 mmol) isopropylethylamine (DIPEA). The reaction mixture was heated under reflux for 2 h.

The product was isolated by using column chromatography (Petroleum ether:Diethyl ether 80:20) and 0.305 g (yield of theory: 61%) of clean product le I—Il) was obtained.

Result of LC/MS [M+H]+: 499.8; 1H NMR (DMSO- (16; CCl4): 3.66 (3H, s, CH3), 7.45-7.50 (1H, dd, CH-arom.), 7.55-7.58 (1H, d, om), 7.65—7.77 (1H, d, CPI-mom), 7-65—7.77 (11-1, dd, CH-arom. phenylhydrazine), 7.65—7.77 (1H, d, CH—arom. phenylhydrazine), 7.85 (1H, s, CH—arom phenylhydrazine), 8,56 (111, s, 1—pyrazole) The synthesis of the methyl ester compounds of examples 1—1, 1-3, 1-4, 1—5, [-7, 1-12, 1-14, I- 33, 1-46, [—47, 1-48, 1—50, L51, 1-52, 1-53, I~54, 1-61, 1—67, 1—68, 1-69, 1—70, 1-73, 1-74, 1-79, I‘- 80, 1-81, 1-82, 1-84, 1-85, 1—86, 1-87, 1-88, 1-92, 1-95, I-96, I—97, 1-106, 1—107, I-109, 1-111, I- 116, I-119, 13—20 and 113-311 was ted in analogy to the above synthesis of the compound of e I~11, using the appropriately substituted methyl 5-(1—(dimethy1a1nino)— 4,4,4mtrifluoro—3—oxobut-l—enn2-yl)—3—phenylisoxazole—4—carboxylate building blocks and the appropriately substituted arylhydrazine derivatives.

The following examples were sized in analogy but using a yl hydrazine: examples 1-28, 1—65, 1—66, I-102, L103 and 1-104, incorporating isobutylhydrazine, (2,2,2- trifluoroethyl)hydrazine, isopropylhydrazine, (2—methoxyethyl)hydrazine and 3— hydrazinyltetrahydrothiophene 1,1—dioxide and 1—(Z—hydrazinylethyl)piperidine respectively.

Synthesis of methyl hloro—6-fluorophenyl)(1-(2-hydroxyethyl)—5- (trifluoromethyl)—1H-pyrazol—4-yl)isoxazole—4-carboxylate (example I~83) To a solution of methyl 3-(2-chloro—6-fluorophenyl)—5-(1~(2—rnethoxyethyl) (trifluoromethyl)-lH—pyrazol-4—yl)isoxazole—4—carboxylate (example 1-102) (27 mg, 0.06 mmol) in CH2C12 (1 mL) was added bromide (0.06 The mixture was stirred at 0°C for l h. The mixture was poured into iced water and extracted with ethyl acetate.The organic layer was dried over sodium sulfate, filtered and concentrated under reduced re.

The resulting oil was purified by pTLC (PEzEE 1:1) to yield example 1-83 as an oil (10 mg, 34%).

Synthesis of ethyl hloro—6wfluorophenyl)-5—(1-(2-chlorophenyl)—5-(trifluoromethyl)- IH~pyrazol~4nyl)isoxazole—4-carboxylate ( example 113—63) hug c; The reaction was carried out ously to the above reaction of example 11, wherein, however, the respective methyl ester was replaced by an ethyl ester building block and 3~ Chlorophenylhydrazine was replaced by 2—Chlorophenylhydrazine.

The synthesis of the ethyl ester compounds of examples L42, IB-3, IB-4, IB-S, IB-6, IB-7, IB-8, 113-9, 13-10, IB-l 1, IB~12, 113-13, IB-14, IB-lS, 13—16, 13-17, 13—32, IB-37, IB~38, 113-40, IBw41, 1843, 113-44, IB-45, IB—46, 113-47, IB~70, IB-—72, 113-84, IB-90, 113-94, IB-95, IB~99 and 113-103 was conducted in analogy to the above synthesis of the compound of example , using the appropriately substituted ethyl 5-(l—(dimethylamino)—4,4,4- trifluoro-3—oxobut-1~en—2—yl)—3-phenylisoxazole-4—carboxylate building blocks and the appropriately substituted arylhydrazine derivatives. e 18—2 and 13-81 were synthesized in analogy but using (2—methoxyethyl)hydrazine and ahydro—2H—pyran—4—yl)methyi)hydrazine, respectively, instead of an aryl hydrazine. sis of ethyl 3-(2-ch10r0-6—flu0rophenyl)—5-(1-(2-fluorobenzyl)—5—(trifluoromethyl)- azol—4-yl)isoxazolecarboxylate le 113—80) Eli/VarF HN’NHZ 4* >4vo o g _m* \t gr W© —*\ C‘ F F __—_______.__.. F F0 0 To a solution of terthutyl carbazate (Hydrazinecarboxylic acid tert-butyl ester) (0.3g 2.3 mmol) and 2-Fluorobenzy1 bromide (0.4g, 2.3 mmol) in dichloromethane (4 mL) was added triethylamine (0.3 mL, 2.3 mmolj. The mixture was stirred at 70°C for 4h. The mixture was then diluted in ethyl acetate and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure to give 380 mg as a white solid (yield 76 %). 1H C13): 1,45 (s, 9H), 4,052 (5, 2H), 7,00-7,40 (m, 4H) Tert—butyl 2—(2—fluorobenzyl)hydrazinecarboxylate (0.5g, 2.27 mmol) ved in dichloromethane (4 mL) was treated with HCl 4M in dioxane (0.8 mL, 22.7 mmol). The mixture was stirred at room temperature for 1.5h. The solvent was concentrated under reduced pressure. The product was lyophillized to give the unprotected benzylhydrazine as a white solid (200 mg, yield 66%). The last step (formation of the N—substituted pyrazole unit) was performed as described for example 1-11 and gave 489 mg of the product as a pale yellow solid (yield 81 %). Result of LC/MS [M+H]+: 512,04; 1H NMR (CDClg): 1,03 (t, 3H), 4,12 (q, 2H), 5,61 (s, 2H), 7,10 (m, 4H), 7,38-7,48 (m, 3H), 8,04 (s, 1H).

The synthesis of the compounds of examples I~101, IB—SS, 13-96, IB-97 and IB—104 was conducted in analogy to the above synthesis of the compound of example 113-80. 2012/051360 Synthesis of 3-(Z-chloro-fi-fluorophenyl)-5—(1—(3—chlorophenyl)—5—(trifluoromethyl)—1H- pyrazol—4-yl)-N-methoxy—N-methylisoxazoIecarboxamide (example 1—63) DIPEA F 0 IN‘b‘ 4“ hi \ /O\ \ ’ E c. Na Cl 0 N,O-Dimethylhydroxylamine (1.780 g, 18.243 mmol) was dissolved in dry THF (100 mL).

The solution was cooled to 0°C and DIPEA (3.0 ml, 18.2427 mmol) was added. 3—(2-Chloro~ 6—fluorophenyl)—5—methylisoxazoleearb0nyl chloride was then added in portions and the mixture was stirred at room ature overnight. The solvent was evaporated. Water added and the flask was placed in the erator for 2 days. The obtained white solid filtered, washed with a 5% aqueous solution of NaHC03, and dried to give 5.2 g of the b amide as a White solid (yield 95 %), Conversion of the Weinreb amide 3-(2~chloro—6-fluorophenyl)-N—methoxy~N,5— dimethylisoxazole-4uearboxamide into 3—(2—ehloro~6—flu0rophenyl)(1—(dimethy1amino)~ —trifluoro—3~oxobut-l—en—2—yl)—N-methoxy—N—methylisoxazole—4—earboxamide and subsequently into the final product of example 1-63 was carried out analogously to the aforementioned synthesis of example I~11.

The synthesis of the compound of example 1-135 was conducted in analogy to the above synthesis of the compound of example 1-63.

Saponification, esterification and amidation procedures Synthesis of 3—(2-chloroflu0rophenyl)(1-(2-fluorophenyl)—5-(trifluoromethyl)-1H— pyrazolyl)-N-methylisoxazole-4—carboxamide (example I-19) F36 :© F30 I) C! hf/0 NaOH CI N’O / N I / / [:1 ’N ——~II- F F 0‘ “i D HNMe o CE N’ r: sozel2 /!}f HCE / I / / I)! —> ’N ”N _m.>.

F0 Et3N F0 NH Saponification: 100 mg (0.27 mmol) of compound of example 1—1 were dissolved in a e of 10 mL ethanol/water 1:1 and a solution of 100 mg NaOH (2.5 mmol) in 5 mL of water was added.

The mixture was heated under reflux for 30 minutes. The ethanol was ated in the vacuum and water was added to adjust the volume to 10 mL. The mixture was filtered to remove unsoluble material and the solution adjusted to pH 1 with concentrated HCl. The precipitate which developed was collected by filtration, washed with water, and dried in the vacuum to yield 91 mg (93%) of 3-(2—chloro-6—fluorophenyl)«5~(1—(2—fluorophenyl)-S* (trifluoromethyl)—lH—pyrazo1—4—y1)isoxazole—4-carboxylic acid.

Amidation: A solution of 91 mg 3—(2—chloro—6—fluoropheny1)—5—(l-(2—fluoropheny1)—5—(trifluoromethy1)— 1H-pyrazolm4—yl)isoxazoIe—4woarboxylic acid (0.197 mmol) in 5 mL 802C12 was heated under reflux for 2 hours. The solution was concentrated in the vacuum and dried in the high vacuum. The residue 3—(2—ehloro—6-fluorophenyl)—5—(1~(2-fiuorophenyl)—5—(trifluoromethyl)— 1H—pyrazoi—4—yl)isoxazole—4-carbonyl chloride was, without further purification, dissolved in 3 mL dry dioxane. To this solution 60 mg (0.88 mmol) amine hydrochloride and 1.96 mL triethylamine was added. The reaction mixture was d at room temperature for 2 hours. The reaction e was concentrated in the vacuum and the residue triturated with hexane. The precipitate collected by filtration and 30 mg (31%) of example 1-19 were obtained. Result of LC/MS : 482.9; 1H NMR (DMSO— (16; CC14): 2609—2619 (3H, CH3), 7.419—7.737 (7H, m, arom.), 8.16] (1H, 3, NH), 8.472 (CH—pyrazole) The synthesis of the N-methyi carboxamides of examples 1—32, 1-37, 1-55, 1-56, 1-57, I—SS, 1- 59, 1—60, I~62, 1—75, 1-93, 1-96, 1-98, I~105, 1-110, and 1—113, was conducted in analogy to the above synthesis of the compound of example 19.

The foilowing acid compounds were obtained using the saponification protocol described above for the tion of 3—(2—chloro—6—fluorophenyl)—5—(l-(2-fluorphenyl)~5m (trifluoromethyl)—lH—pyrazol~4-yl)isoxazolecarboxylic acid: examples I—91, 1-108, 1-114, IB—IS, 113—19, IB-42, and IB~86.

Synthesis of 3-(2-chlor0-6—fluorophenyl)(l-(3-chlor0phenyl)—5-(trifluoromethyl)-1H- pyrazol—4-yl)isoxazoEe—4—carboxamide (example 1-121) CI Cl 3‘ F FF F F Q NaOH FF F NH4Cl Ci N-O C; I N'O . / N ' / / N Cl Q 1/ »I\'I EtOH ' / “N —N HBTU DIPEA F0 NH;I F0 O OH DMA \ F0 Saponification of the ester of example 1—11 was achieved following the description for example 1-19, first step, to give hIoro—6—fluorophenyl)—5—(l~(3—chlorophenyl)—5- (trifluoromethyi)—lH—pyrazol—4~yl)isoxazolecarboxylic acid in 89% yield. To a solution of 6.0 g (12.34 mmoi) 3—(2—chloro—6—fluorophenyl)—5—(l—(3—chlorophenyl)—5—(trifluorornethyl)— lH-pyrazol—4—y1)isoxazole-4—carboxylic acid and 1.98 g 1 mmol) umchlorid in ml. dry DMA 9.36 g (24.681 mmol) HBTU and 6.45 mL (37.021mmol) DIPEA were added. The mixture was stirred 3 hours at r.t.. Ethylacetate was added to the reaction mixture and it was washed twice with sodium hydrogen carbonate (5%, aq) and citric acid (5%, aq).

The c layer was dried over anhydrous magnesium sulfate and the solvent was removed in the vacuum. The oily residue became solid by drying in the vacuum. The solid was washed with petroleum ether, filtrated and dried in the vacuum to yield 5.37 g (90%) of example I- 121. Result of LC/MS MH+: 484,83; 1H NMR (DMSO—dfi; CC14): 7394.78 (7H, m, CH- arom. / 2H NHg), 8.43 (1H, s, CanyraZ.) The synthesis of the carboxamide of example 1-124 was conducted in y to the above synthesis of the compound of example 1-121. rmore, the synthesis of the following differently N—substituted carboxamides was conducted in analogy to the above synthesis of the compound of example 1-121, in each case 2012/051360 using the appropriate amine: examples L2, [-16, 1-17, 1-18, [-20, I—21, I-22, 1-23, 1-24, 1-118, 1—127, and 1-132.

Synthesis of (3-(2-ch10r0—6-fluor0phenyl)(1-(3—chlorophenyl)-5—(triflu0romethyl)—1H- pyrazolyl)isoxazol—4-yl)(morpholino)methanone (example IB—35) HOBt, EDCI, NMM 3~(2~eh10ro—6-flu0rophenyl)—5~(1 lorOphenyl)—5—(trifluoromethy1)—1H—pyrazol—4- y1)isoxazoie~4—carboxyiic acid (50 mg, 0.0001 mmol), Morphoiine (9 mg, 0.0001 mmol), HOBt (14 mg, 0.0001 mmoi) and EDCI (19 mg 0.00012 mmol) were dissolved in 1 mL dry DMF. N—Methylmorpholine (100 uL, 0.001 mmol) was added and the on mixture d at room temperature overnight. Morpholine, HOBt, EDCI and N-Methylmorpholine were added again in the aforementioned ratios. The mixture was stirred at room ature for 24h. DMF was removed by evaporation. An aqueous solution of 5% citric acid was added.

The precipitate was filtered and dried. The product (example 11365) was purified by pTLC (PE/EB 5/5) to give 26 mg of a yellow oil (yield 45 %). Result of LC/MS Nil-1+: 554,7; 1H NMR (CDC13): 8.15 (1H, s, CH—pyraz.), 7,35-7,6 (6H, m, CH-arom), 7,15 (1H, t, CH—arom), 3,6 (4H, m, CHZ—morpholine), 3,18 (4H, m, CHg-morpholine).

Further amide compounds were ed as described above for compound 13-35, in each case by using the appropriate amine: examples 1334, 113-49, IB-SO, IB-Sl, 113-52, 113-53, IB- 54, 18-55, 11356, IB—57, IB-SS, IBn59, 113—62, 113-63, 113-64, 113—65, 113-66, IB-74, 13—87, IB- 88, 13-91, IB-93, and [13—100 (in the latter case, the amide formation was applied to the substituent at the aryl unit of the N—arpryrazole moiety).

WO 01263 Synthesis of 3-(2-chloro-fi-fluorophenyl)—5-(1-(3-chlorophenyl)(trifluoromethyl)—1H- 1—4~yl)~N-methoxy-N-methylisoxazoleA—carboxamide (example 1-63) HBTU DIPEA To a solution of 10,8 g (22,2 mmol) 3~(2-chioro—6—fluorophenyl)—5-(1—(3—chlorophenyl) (trifluoromethyi)—1H-pyrazolm4-yl)isoxazole—4—carboxylic acid, 2,17 g (leq) N,O— Dimethylhydroxylamine and 8,42 g (leq) HBTU in dimethylhydroxylamine 3,68 rnL DIPEA were added. The mixture was d overnight at r.t. The solvent was removed in the vacuum.

The e was resolved in ethylacetate and extracted with sodium en carbonate (5%, aq) and Citric acid (5%, aq). The c layer was dried over anhydrous magnesium sulfate and the solvent was removed in the vacuum. TLC (6:4 petrolether:ethylacetate) showed residual educt. The product was isolated by column chromatoghraphy (6:4) petrolether:ethylacetate). The product (example 1-63) was dried under vacuum to yield 2.28g (19%). Result of LC/MS Nil-1+: 528.8; 3H NMR (DMSO-dé; CC14): 3.08 (3H, s, CH3), 3.36 (3H, s, CH3), 7.40—7.81 (7H, m, CH—arorn.), 8.39 (1H, s, CH—pyraz.) Compound of example L94 was obtained in analogy to the protocol of compound 1-63.

Esterification: Synthesis of Ethyl 3-(2-chloro~6~fluor0phenyi)—5~[1-(2-fluor0phenyl)(trifluoromethyl)- azol—4—yl]isoxazolecarboxylate (example 1—42) To a suspension of 3—(2-chlorofluorophenyl)—5-(1—(2—fluorophenyl)-5—(triflu0romethyl)~ 1H—pyrazol—4—yl)isoxazole—4—carbonyl chloride (0.1 g) and ethanol (0.04 mL) in CH2C12 (1 mL) Hydroxybenzotriazole (HOBT) (50 mg) and 1—ethyl—3—(3-dimethylaminopropyl) carbodiimide (EDC) (45 mg) were added, the reaction mixture was stirred occasionally until clear solution was formed and allowed to stay overnight. The solution was diluted with water and the separated organic layer was purified by column chromatography (CHC13) to give ester compound of example 1-42 (yield 75%). Result of LC/MS [M+H]+: 497.8; 1H NMR (DMSO— (16, CC14)Z 1.03 (3H, t, CH3), 4.10 (2H, q, CH2), 7.32 (1H, t, CH—arom.), 7.42—7.71 (6H m, CH- arom.), 8.43 (1H, s, az.).

The synthesis of the compounds of examples L77, 1-78, 1-90, L99, 1-100, and 1-112 conducted in analogy to the above sis ofthe compound of example 1—42.

Synthesis of inPropyl 3—(2—chloro-6—fluorophenyl)[1~(2—f1uorophenyl)—5- (trifluoromethyl)-1H-pyrazol—4—yl]isoxazolecarboxylate (example I-43) 2—iodopropane CsF _N ;: F0 0 3 ~(2—chloro—6-fluorophenyl)(l —(2—fluorophenyl)—5-(trifluoromethy1)— 1 zol—4— yl)isoxazole—4—carboxylic acid (30 mg, 0,064 mmol), cesium fluoride (12 mg, 0,077 mmol) and 2-iodopropane (0,008 mL, 0,077 mmol) were dissolved in dried acetonitrile (1 mL) and the e was d for 2011. The mixture was d with dichloromethane and washed with water. The organic phase was dried over NaZSO4, filtered and the solvent was solvent removed under reduced pressure. The product was purified by pTLC (PE/EB 9/1) to give 26mg ofa yellow oil (yield 79 %). Result of LC/MS {NIH-1f: 511.8; 2H NMR (CDClg): 1.02 (6H, d, 2 x CH3), 5,02 (1H, m, CH~propyl), 7.18 (1H, t, CH-arom.), 7.28—7.61 (6H m, CH- arom.), 8.31 (1H, s, CH-pyraz.).

The synthesis of the compounds of examples , IB-60, IB-GI, IB-73, 13—78, [13-79, and [13-82 was conducted in analogy to the above synthesis of the compound of example 1-43.

Synthesis of 5-(1~(3—acetamidophenyl)(trifluoromethy1)—1H~pyrazoI-4—yl)—3—(2-chloro- 6~fluorophenyl)isoxazole—4-carboxylate (example IB~89) CH3], CsF The same esterification procedure as described above for e 1—43 was applied, replacing 2—iodopropoane by iodomethane to give methyl ester of example IB~89 as a yellow oil (yield %).

Synthesis of methyl 3-(2—chloro-6—fluorophenyl)(1-(pyridin-S-yl)(trifluoromethyl)- azol—4-yl)isoxazole-4—carboxylate (example 113—67) To a mixture of 3—(2—chloro—6—fluorophenyl)—5-(1~(pyridin—3—y1)—5—(trifluoromethyl)-1H— pyrazol—4—yl)isoxazole-4—carb0xylic acid (30 mg, 0.1 mmol) in methanol (1.5 mL) was added thionylchloride (5 ML, 0.1 mmol). The mixture was stirred at room ature for 60h and for 511 at reflux. The mixture was diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure. The product (example IB~67) was purified by pTLC (1:1 EE/PE) to give 3 mg of a white solid (yield 9%).

Result of LC/MS MH+z 466,76; 1H NMR (CDCl3): 3,19 (s, 3 H), 7,15 (t, 1H), 733—755 (m, 611), 8,25 (s, 1H) The synthesis of the compounds of examples IB-69, IB-‘Tl, 113-75, IB~76, 13-77, 113-92 conducted in analogy to the above synthesis of the compound of example IB—67.

Synthesis of S-methyl 3-(2-chloro-6—fluorophenyl)—5-(1~(pyridinyl)—S- (trifluoromethyl)-1H-pyrazolyl)isoxazolew4-carbothioate (example IB-68) 3 —(2—chloro-6—fluorophenyl)—5 —(1—(pyridin—3 —yl)—5—(trifluoromethyl)— l H—pyrazol~4~ yl)isoxazolecarboxylic acid (30 mg, 0.066 mmol) was treated with thionylchloride (l.5 mL) and stirred at reflux for 2 h. The mixture was concentrated under reduced pressure. The intermediate was treated with benzene (3x) and the benzene was ated to remove water.

Then, the obtained mixture was ved in benzene(1,5mL) and sodium methanethiolate (32.5 mg, 0.46 mmol) was added. The reaction mixture was stirred at reflux for 5h. The mixture was diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure. The product (example IB-68) was purified by pTLC (1:1 EE/PE) to give 3 mg of a white solid (yield 9 %). Result of LC/MS NIH-H 482,76; 1H NMR (CDC13)Z 2,33 (t, 3 H), 7,19 (t, 1H), 7,33-7,55 (m, 6H), 8,23 (s, 1H) Synthesis of S-methyl 3-(2-chloro-G-fluorophenyl)(1—(3-chlorophenyl)—5— (trifluoromethyl)—1H—pyrazolyl)isoxazole—4—carbothioate (example I-126) GHQ!»soon MG Cl OH N O \S ,N C—HLSNE \ N;© NOFFF NOF f GIN-OFF Carboxylic acid 3-(2—chloro-6—fluorophenyl)—5—(1-(3—chlorophenyl)(trifluoromethyl)-1H~ l—4—yl)isoxazole—4—carboxylic acid (60 mg, 0.123 mmol) was d in SOC12 (5 ml.) for 2 hours and an excess of thionyl chloride was evaporated. The residue was dissolved in dry dioxane (5 mL), sodium thiornethoxide (60 mg, 0.86 mmol) was added and the e was d for 1 day. After evaporation of the solvent, water (5 mL) was added to the residue.

The e was stirred for 30 min at r.t. and the supernatant was poured off the resulting resin. The product was isolated from this resin by column chromatography (silica gel 0.040- 0100 mm, eluent — chloroform : hexane = 1: 1). Yield of example [-126: 45 mg (71%) of a slightly grayish resin. Result of Loans” MHe: 515.9; 1H NMR (DMSO—dg; con): 2.30 (s, 3 H) 7.37 (t, J=8.66 Hz, 1 H) 7.49 (d, J£8.03 Hz, 1 H) 7.53 — 7.61 (in= l H) 7.61 - 7.73 (m, 4 H) 8.36 (s, 1 H) The synthesis of the compounds of examples {-128 and I-130 was conducted in analogy to the above sis of the compound of example I426.

Synthesis of hloro—6~fluorophenyI)—5—(1-(3-chlorophenyl)(trifluoromethyl)—1H— pyrazol—4~yl)-N-methylisoxazoleearb0thioamide (example L72) ,NO FF F Lawesson N'O F FF reagent If NH NNQC Fs NH ~NN‘Q " Ci A mixture of compound of example I—19 0.37 g, 0.74 mmol, Lawesson reagent (0.30 g, 0.74 mmol) and dry dioxane (10 mL) was refluxed for 1.5 hours. The solvent was evaporated in vacuum to dryness and the residue llized from ethanol (20 mL).

Yield of compound L72: 0.28 g (73%), yellowish crystals. Result of LC/MS MPH: 516.3; 1H NMR (DMSO'dfi; CC14): 3.03 (d, J=4.52 Hz, 3 H) 7.25 (t, £18.53 Hz, 1 H) 7.38 (d, J=8.03 Hz, 1 H) 7.48 ~ 7.57 (m, 2 H) 7.58 ~ 7.67 (In, 3 H) 8.05 (s, 1 H) 10.31 (d,J=4.52 Hz, 1 H) The synthesis of the compounds of examples I—76, [-122, [-123, v125, I-129, 13-101 and IB- 102 was conducted in analogy to the above synthesis of the compound of example I—72.

Result ofLC/MS Mlle: 502.3 Synthesis of 3-(2-chlorofluorophenyI)—5—(1-(4-fluorophe11yl)(trifluor0methyl)—1H- pyrazol—4—yl)isoxazole (example I-25) [5/ o o F 0 F 0 NV s W__ HZN + OA ““o/L / * O FF I Elm—O——\F M F0” 7 DAN O N; ~ N_.r F I ethyl 1-(4-fluorophenyl)(trifluoromethyl)-1H-pyrazole—4—carboxylate: Ethyl 4,4,4—trifluoroacetoacetate (18.5g, 77.34 Inmol) and N,N—Di1nethylformamide dimethyl acetal ; ,77.34 mmol) were dissolved in benzene (10 1nL). The mixture was heated under reflux for l h. The t was evaporated und distilled with a Kugelrohr apparatus to give 12 g of ethyl 2-((dimethylamino)methylene)—4,4,4-—trifluoro—3-oxobutanoate (yield 65 %).

Phenylhydrazine (2.625;, 20.82 mmol) was ved in anhydrous THF (100 mL) and triethylamine (2.9 mL, 20.82 mmol) was added. The solution was cooled to 40°C. A solution 2O of ethyl 2—((dimethylamino)methylene)-4,4,4-trifluoro—3—oxobutanoate (5 g, 20.82 mmol) in mL THF was added dropwise in 1h. The mixture was then stirred 30 min at "10°C and then 16 h at room temperature. The solvent was evaporated. The obtained oil was dissolved in ethylacetate and washed with a solution of sodium hydrogencarbonate and citric acid. The organic phase was dried over magnesium sulfate, filtered and ated. The product was purified by column chromatography (80:20 PE:EE) to give 2.8 g of ethyl 1-(4-fluorophenyl)~ -(trifluorornethyl)— 1 Hupyrazole—ll—carhoxylate (yield 44 %).

,OH F F F F c: C' ”E /\o F 540M THF dry F + UM ——~4«-m-au / / PlQ’F 0 / pi 0°C 'N F “N under argon F To a solution of 1.9243 g (10.2571 mmol) (2-chloro—6-fluorophenyl)ethanone oxime in mL dry THF 8 mL (2 eq.) n—Butyllithium were added se under argon and icebath cooling. 1.55 g (0.5 eq.) of ethyl l-(4—fluorophenyl)(trifluoromethyl)-lH—pyrazole—4- carboxylate were dissolved in 5 mL dry THF and also added within 5 minutes. The solution was stirred for 15 minutes at 0°C.

To this reaction mixture 40 mL hydrochloric acid (10% solution in water) were added. The mixture was heated under reflux for 1 h. The aqueous on was extracted three times with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed in vacuo, TLC (4:1 hexanezethyl acetate) showed l spots of impurities.

The product was purified by flash chromatography on silica gel with hexane:ethyl acetate 4:1 and 355 mg (yield of theory 48%) of compound I-25 were ed. LC/MS MH+ : 4260; 1H NMR (DMSO- d6; CC14): 7.17 (1H, s, isooxazole); 7.42—7.71 (7H, m, ; 8.48 (1H, s, pyrazole) Synthesis of (E)—3-(2-chloro—6—fluorophenyl)—5-(2—(dimethylamino)vinyl)isoxazole carbonitrile F / \ 0 dry toluene / M<N_ 7 h reflux Ci Bredereek’s reagent To a solution of 1.5 g (6,3389 mmol) 3—(2-chloro—6—fluoropheny1)—5—methy1isoxazole—4~ carbonitrile in 100 mL dry toluene, were added 2.10 g (12.6779 mmol) tert-Butoxy— bis(dimethylamino)methane. The reaction mixture was heated under reflux for 12 h. The e was concentrated in vacuo and was dried in the high vacuum. Petroleum ether added to the crystallized e. The product was collected by filtration and 1.791 g (yield of theory: 95.9%) of clean product were obtained. Result of LC/MS MH+3 292.0; 1H NMR (DMSO— (16; CC14): 2.93 (3H, s, N-CH3), 3.17 (3H, s, N-CH3), .20 (1H, d, C2112), 7.74— 7.78 (1H, d , C2112), 7.45—7.52 (1H, dd, CH-arom.), 7.57—7.59 (1H, d, (EH-arena), 7.65-7.71 (1H, d, CH—arom.) 2012/051360 Synthesis of (Z)(2-chloro-fi-fluorophenyi)—5—(l—(dimethylamino)-4,4,4—triflu0ro—3- oxobut—l-en-2~yl)isoxazoIecarbonitrile To a solution of 0.5 g (1.7140 mmol) (E)—3—(2-chloro—6-fluoropheny1)«5—(2~ (dimethylamino)vinyl)isoxazole—4-oarbonitrile in 20 mL dry romethane, were added dropwise under ice-bath cooling 0.36 1111.. (2.5710 mmol) roacetic anhydride. The reaction mixture was stirred for 2 h at r.t.. Afterwards the mixture was concentrated in vacuo and was dried in the high , Petroleum ether was added to the crystallized product and was collected by filtration to obtain 0.625 g (yield of theory: 94%) of clean product. Result of LC/MS MH+: 388.0; 1H NMR (DMSO'dfi; CCl4): 2,75 (3H, s, N-CHg), 3.46 (3H, s, N-CHg), 7.53-7.59 (1H, dd, CH—arorn.), 7—64n7.67 (1H, d, CH-arom.), 7.73—7.81 (1H, d, CH-arom.), 8.23 (ll-I, s, CH) Synthesis of 3-(2-chlorofluor0phenyI)(1-(3-chloropheuyl)(trifluoromethyl)—1H- pyrazoI-4—yl)isoxazolecarbonitrile (example L49) \\ \N‘C;2“. /l\ k F dryethanol + + N T ClQ N’NHZ H K 3 h reflux To a solution of 0.1 g (0.2579 mmol) (Z)—3—(2~ch10ro~6~fluorophenyl)—5-(1—(dimethy1amino)- 4,4,4~trifluoro—3—oxobut—l—en—2—y1)isoxazole—4—carbonitrile in dry ethanol, were added 0.0462 g (0.2579 mmol) 3—Chlorophenylhydrazine and 0.78 mL (0.2579 mmol) DIPEA. The reaction mixture was heated under reflux for 3 h. The mixture was trated in vacuo and was dried in the high vacuum. The upper spot was isolated by using the preparative ayer chromatography and 0.0037 g (yield of theory: 3.0%) of clean product compound 1-49 were obtained. Result of LC/MS MIT: 466.9; IH NMR (DMSO— (16; CCla): 7.73-7.97 (6H, m, CH- arom.), 8.04 (1H, s, CH—arom.), 8.81 (1H, s, CH—pyraz.) The sis of the compound of example 1-120 was conducted in analogy to the above synthesis ofthe compound of example L49.

Synthesis of Synthesis of 3—(2—chlorofluorophenyl)—5—(1-(3-chlor0phenyl)—5— (trifluoromethyl)—1H-pyrazolyl)—N-methylisoxazolecarbothi0amide (example 1-64) To a cooled (frozen) solution of (E)—methyl 3-(2-chlore—6—fluoropl1enyl)-5—(2— hylamin0)vinyl)isoxazole-4—carboxylate (85 mg, 0.26 mmol) a mixture of absolute dioxane (2.3 g) and Hfinig‘s base (156 mg, 1.20 mmol) 2,2,3,3—tetrafluoropropan0yl chloride (129 mg, 0.76 mmol) was added. Reaction e (solution) was left to melt and kept for 1.5 h at It TLC in EtOAc/C7H16 9/1 showed no starting material and a single product.

Solution was evaporated to dryness, oily residue was d by boiling hexane which was concentrated to give pure (E)—methyl 3~(2-chloro—6-fluoropheny1)-5~(l—(dimethylamin0)- 4,4,5,5—tetrafluoro-3~oxopent—1—enyl)isoxazolecarboxylate. The Residual 0in (E)- methyl 3—(2—ch1oro—6-fluor0phenyl)—5-( l —(dimethylamino)—4,4,5, 5 —tetrafluor0—3 ~0xopent— 1 en- 2-y1)isoxazole—4—carb0xylate was used for further reactions without additional ation.

Treating raw (E)-methy1 3~(2—chloro—6—fluoropheny1)—5—(1-(dimethyiamino)—4,4,5,5— tetrafluoro-3 —oxopent~1«en—2—yl)isoxazole—4—carboxylate (116 mg) by 3~fluorophenyl hydrazine hydrochloride (42 mg) in ethanol by standard procedure gave 96 mg (73%) of pure compound L64. Result of LC/MS MH+: 5168; IH NMR (400 MHZ, DMSO—dé) Bppm 3.55 - 3.78 (m, 13 H) 6.55 — 6.95 (In, 5 H) 7.24 — 7.53 (m, 20 H) 7.55 - 7.73 (m, 8 H) 8.33 (s, 4 H) Synthesis of methyl 3-(2—chlor0—6-flu0rophenyl)(1-(3-fluor0phenyl)—5~ (trifluoromethyl)-IH-pyrazol—4-yl)isothiazolecarhoxylate le 1-137) NaOH 0.32 g 3—(2—chloro—6—flu0rophenyl)-5—(1—(3—flu0r0phenyl)—5~(trifluoromethyl)—1H—pyrazol—4~ yl)isoxazole—4—carboxy1ic acid (0.70 mmol) was dissolved in water NaOH solution (20 mL water + 0.115 g NaOH). Bromine (0.34 g, 2.1 mmol) was added slowly and dropwise to this solution at stirring and cooling (0 m 5°C). ng ued for 2 hours at 0 — 5°C and for 2 days at r.t. The precipitate was filtered off and suspended in 5% water NaOH on (10 niL). After 2 hours of stirring solids were filtered off, washed with water and dried on air to a yield of 0.15 g (0.30 mmoi, 42%) of compound 1-137 as white ls. Result of LC/MS MH+: 505.7; IH NMR (DMSO—dé; CCl4): 7.35 — 7.48 (m, 4 H) 7.52 (d,J=8.28 Hz, 1 H) 7.61 — 7.74011, 2 H) 8.4 (s, l H) Further examples which were obtained in analogy to the protocol of example 1-137 are: 1-140, 1-144, 1-145, IB-23, IB—24, {Bo—2.5, IB-26, 13-27, 13-28, and IB-83.

Synthesis of methyl 3-(2-chloro—6—fluorophenyl)(I-(3-fluorophenyl)—S— (trifluoromethyl)—lH-pyrazol—4-yl)isothiazolecarboxylate (example 1-133) o'Q‘fl ca Solution of 102 mg (0.217 mmol) of 3-(2—chloro—6—fluorophenyl)~5—(l-(3—fluorophenyl)-5« (trifiuoromethyi)-lpryrazol—4—yl)isoxazole-4—carboxylic acid in 8 mL SOC12 was refluxed for 3 h. Volatiles were ated in vacuum thoroughly. The residue was dissolved in 8 mL absolute dioxane and added at stirring dropwise to a mixture of 825 mg N2H4*H20 and 6 mL absolute dioxane. TLC of reaction mixture showed new product with Rf less that starting acid in heptane, 1/1' and greater — in EtOAc/Eth. les were evaporated, water was added to residue to precipitate an 0in pink solid. Water was removed, residue was washed by water, than treated by 5 mL water with 10 drops ofACOH and finally washed by water.

Product was partially extracted by boiling heptane (38 mg) and partially extracted by ether with further treatment of the ether solution by heptane (39 mg). Total yield: 77 mg (73%) of compound 1—133. Result of LC/MS MHt: 484.8; 1H NMR (DMSO—d6; CCl4): 4.49 (2H, 5, NH;), 7.44—7.79 (7H, m, CH—arom.), 8.44 (1H, s, CH—pyraz.), 9.54 (1H, 5, NH) e 1-134 was synthesized ing to the protocol described for exampie 1-133. sis of 3~(2-chloro—6-fluorophenyl)—5—(1-(3—fluorophenyl)~5-(trifluor0methyl)—1H— pyrazol—4-yl)isoxazol—4-amine (example I~117) :- "'1: Compound 1—133 (0.60 g, 1.24 mmol) was dissolved in the mixture of dioxane (20 mL), H20 (5 mL), HCl cone. (1 mL). A solution of NaNOz (0.532 g) in water (10 mL) was added dropwise at stirring and cooling (0-50C). After 30 min of stirring at this temperature the mixture was poured onto ice (approx. 50 g). A resinous residue of crude azide formed. After staying overnight in a refrigerator the supernatant was decanted. The residue was dissolved in the e of dioxane (20 mL) and water (6 mL) and refluxed for 30 min. The solvent evaporated to s in vacuum. The residue was dissolved in a minimal amount of chloroform and pure product was isolated by column chromatography (silica gel 0.040— 0100 mm, eluent —- chloroform, Rf z 0.3). Yield of compound 1-117: 0.324 g (0.73 mmol, 59%) of a yellowish solid. Result of LC/MS MH+: 440.94; 1H NMR (DMSO—d6; CC14): 4.56 (2H, s, NHZ), 7.36—7.68 (7H, m, Gil-mom), 8.36 (1H, s, CH—pyraz.) Example IB-36 was synthesized according to the protocol described for example I-«117.

Synthesis of N—(3—(Z-chloro-G-fluorophenyl)-5—(1—(3-fluorophenyl)(trifluoromethyl)- 1H-pyrazol—4—yl)isoxazol~4-yl)acetamide le 1-139) A mixture of compound 1-117 (0.167 g, 0.38 mmol) and acetic anhydride (3 mL) was refluxed for 2 hours (until absence of starting amine by TLC). After cooling, water (15 mL) was added and the reaction mixture was d for 1 hour. The supernatant was removed from the oily precipitate of crude product. Purification by column tography a gel 0.0400100 mm, eluent w chloroform, Rf z 0.25) gave an oil, which solidified after treatment with hexane. Yield of nd I—139: 0.112 g (0.23 mmol, 61%) of a yellowish solid.

Result of LC/MS MH+2 4838; 1H NMR (DMSO—dg; CC14): 1.90 (s, 3 H) 7.28 (t, J=8.66 Hz, 1 H) 7.33 — 7.46 (In, 4 H) 7.50 - 7.59 (m, 1 H) 7.59 — 7.68 (m, l H) 8.22 (s, 1 H) 9.55 (s, 1 H) Example IB—39 was synthesized according to the protocol described for e I-139.

Synthesis of N-(3—(2-chloro-fi—fluorophenyl)—5-(1—(3«chlorophenyD-S—(trifluoromethyl)- 1H-pyrazolyl)isoxazolyl)formamide (example IB-48) 3—(2—chlorc—6—fluorophenyl)—5—(l —(3~chlorophenyl)—5 ~(trifluoromethyl)— l H-pyrazol—4— yl)isoxazol—4—amine (example [3—36) (40mg, 0,1 mmol) was dissolved in formic acid (3 mL).

The mixture was stirred at room temperature overnight. To the reaction e was added water. The ing precipitate was ted, washed with water and dried under vacuum.

The t was purified by pTLC (EB/PE 2:1) to give 32 mg of the desired product (example [EB-48) (yield 75%). Result of LC/MS MHe: 484,82; Il-I NMR (CDCI3): 6,63 (t, 1H), 7,22 (m, 1H), 7.38~7.59 (m, 6H), 8,02 (s, 1H) 8.22 (s, 1H) Synthesis of 3-(2-chlor0—6-fluorophenyl)-5—{l-(3-fluorophenyl)—3-(trifluoromethyl)—1H- pyrazol—4-yl]isoxazolnél-ylformamide (example I-141) A solution of 130 mg (0.295 mmol) 3—(2—chloro—6—fluorophenyl)~5—[1—(3—flu0rophcnyl)—3— (trifluoromethyl)-lH—pyrazol—4—yl]isoxazol-4—amine (example {-117) in a mixture of 1847 mg (17.4 mmol) trimethylorthoether and 1660 mg (27.7 mmol) acetic acid was stirred at r.t. for l h. The suspension was filtered, and the obtained white solid salts were washed on the filter with hexane. Filtrates were combined and evaporated to dryness. The residue was treated by hexane, and the extract was purified by CC on silica gel, (eluent EtOAc/hexane 1/1). The obtained fraction of the pure product le 1-141) was evaporated to give 50 mg of a light greenish oil (yield 36%). Result of LC/MS MPH: 469,04; 1H NMR (400 MHZ, methanol—d4): 7.29—7.35 (m, 1 H) 7.44 (s, 3 H) 7.46-7.50 (m, 1 H) 7.57—7.67 (m, 2 H) 7.72 (s, 1 H) 8.26 (s, 1 N—{3—(2-chloro-6—flu0r0phenyl)—5—[1-(3sflaorophenyI)(trifluoromethyl)-1H-pyrazol-4~ yI}-1,2uoxazol-4uyl}—2,2,2~trifluoroacetamide (example 113-22) A mixture of hloro—6—fluorOphenyl)—5—(1—3~fluoropher1yl)—5—(trifluoromethyl)—1H- pyrazol-4—yl)isoxazol—4—amine (example 1-117) (70 mg, 0.159 mmol), dioxane (5 ml) and trifluoroacetic anhydride (50 mg) was stirred at r.t. ght. The solvent was evaporated in vacuum and water (5 ml) was added to the residue. The itate was filtered off, washed with water and dried to give 77 mg of example 13-22 (yield 90.2%). 1H NMR (DMSO—D6, CC14): 7,37 (m, 4H), 7,57 (m 2H), 8,26 (s, 1H), 11,29 (3, 1H).

Synthesis of (Z)—methyl N-(3-(2—chlorofluorophenyi)—5-(1—(3~fluorophenyl)-5— (trifluoromethyl)—1H-pyrazoi—4-yl)isoxazoIyl)-2,2,2-trifluoroaeetimidate (example I— 136) A mixture of example IB-22 (30 mg, 0.056 mmol), acetone (5 m1), anhydrous K2C03 (100 mg) and (II-131 (100 mg) was d at r.t. overnight. Inorganic salts were filtered off and washed with acetone. The filtrate and rinse were combined and the solvent was evaporated in vacuum to give example 1-136 as viscous resin (27 mg, 0.049 mmol, 87.5%) as a mixture of Z and E isomers (According to 1H NMR data). 1H NMR (DMSO-Dé, CC14): 3.24—3.36 (m, 3H), 7.31- 7.57011, 6H), 7.58—7.75 (m 2H), 8.23 (s, 1H). 2012/051360 Synthesis of N'-acetyl—3-(2-chlorofluor0phenyl)~5-(1—(2~fluorophenyl) (trifluoromethyl)—1H—pyrazol—4-y1)isoxazole-4~carb0hydrazide (example 1-142) 0 O )LO/k NH2 F To a solution of 190 mg (0.393 mmol) 3“(Z-chloro—6-fluorophenyl)n5—(1~(2—fiuorophenyl)—5— (trifluoromethyl)—1H-pyrazol—4—y1)isoxazole—4-carbohydrazide (which was synthesized in analogy to the procedure described for example 1—133) in 5.8 m1 absolute dioxane, 148 mg (1.885 mmol) acetyl chloride were added. The conversion is complete within minutes. les were evaporated, residue was re-evaporated with ethanol. Residue was llized from EtOAc - heptane to give 175 mg (85%) of compound 1—142 as a pale yellow powder.

Result of LC/MS Nil—1+: 526.06; 1I—l-NMR (400MHz, methanol—d4) 5 ppm: 1.98 (3H, s, CH3), 7.25-7.32 (1H, m, CH—arom.), 7.41-7.48 (3H, m, CH-arom.), 7.54-7.61 (1H, 111, CH—arorn), 7.64~7.74 (1H, m, CH—arom.), 8.63 (1H, s, CH—pyraz.) sis of 5-(1-(2-aminophenyl)—5-(trifluoromethyl)—1H-pyrazol—4wyl)—3-(2-ch10r0 flucrophenyl)isoxazoleearboxylate (example IB-98) 3—(2—ch10ro—6—f1uoropheny1)—5-(1—(2-nitropheny1)—5—(t1ifluoromethy1)-IH—pyrazol—4— yl)isoxazole~4-carboxylate (example 113—95) (100 mg, 0.19 mmol) was placed in a vial in the presence of acetic acid (1.5 mL) in tetrahydrofuran (2 mL). The solution was stirred and concentrated hydrochloric acid (0.03 mL, 0.19 mmol) and zinc (80.9 mg, 1.24 mmol) were added successively under ice~cooling. The mixture was allowed to stir at rooni temperature for 1211. An s solution of ammonia (25%) was added to the on mixture to alkalify. The e was then extracted with ethyl acetate and the organic layer was washed with brine, dried over MgSO4, filtered and the solvent was removed under reduced pressure.

The product (example IB-98) was purified by pTLC (CHZCIZ/MeOH 100/5) to give 25 mg as a brown/yellow oil (yieid 27%). Result of LC/MS MH+2 ; 1H NMR (CDC13)I 1.05 (t, 3 H), 3,80 (s, 2H), 4,18 (q, 2H), 6,85 (m, 2H), 7,11-7,45 (m, 5H), 8,23 (s, 1H) Synthesis of 2-acetamidophenyl)(triflu0romethyl)—1H—pyrazolyI)—3-(2-chloro- 6-fluorophenyl)isoxazolecarboxylate (example IB-l) To a solution of ethyl 5—(1—(2—aminophenyl)—5—(trifluoromethyl)—lH—pyrazol—4—yl) (2-chloro-6—fluorophenyl)isoxazole-4ucarboxy]ate (example 113-98) (21 mg, 0.04 mmol) in acetic acid (1 mL) was added acetic anhydride (4 uL, 0.04 mmol). The mixture was stirred over night at room temperature. The mixture was diluted with dichloromethane and washed with water (3 x), dried over sodium sulfate, filtered and concentrated under reduced pressure.

The resulting oil was purified by TLC (DCM : MeOH 100:5) to give 3 mg of e IB-l as a yellowish oil (yield 13 %). Result of LC/MS MH+: ; 1H NMR (CD013): 1.05 (t, 3 H), 2,11 (s, 3H), 4,18 (q, 2H), 7,11—7,60 (m, 711), 8,33 (s, 1H) Synthesis of methyl 3—(2~ch!oro-6—fluorophenyl)-5~[1—(3-fluorophenyl)—5- (trifluoromethyl)—lH-pyrazol~4-yl}isoxazol-4aylcarbamate (example I-138) F F CH30H / / / N F HNYO 0\ 3-(2-chloro—6-fluorcpheny1)—5—{1—(3-fluorophenyl)-5—(trifluoromethyD—1H—pyrazol—éi— xazole—4—carb0xy1ic acid (103 mg, 0.219 mmol) was dissolved in thionyl chloride (6 mL) and refluxed for 3h. Volatiles were evaporated in vacuum, the residue was dissolved in absolute benzene («6 mL), and sodium azide (281 mg, 4.322) and 10 drops of triethylamine 2012/051360 were added to the solution (pH < 7). The suspension was stirred for 3h. Volatiles were evaporated in , and the residue was treated with 2 x 10 mL ether. Ethereal extracts were evaporated to give a viscous brown oil. Methanol (~5 mL) was added to the oil and the solution was kept at r.t. for 1 day. Volatiles were evaporated in vacuum, and the residue treated with 2 x 10 mL boiling e followed by evaporation of the solvent, giving 55 crude product. Column chromatography on silica gel (eluent EtOAc/heptane, 1/1 v/v) gave pure methyl 3 —(2—chloro~6—fluorophenyl)-5—[1 -(3-fluorophenyl)—5 —(trifluoromethyl} l Hm pyrazol~4~yl]isoxazol—4—ylcarbamate (example 1—138) (45 mg, 41%). Result of LC/MS MH+: Methyl 3-(2~chloro—6—fluorophenyI)—5-[1-(2-fluorophenyl)—1H-pyrazol—4-yl]isoxazole—4- carboxylate (example 1—89) A) methyl 3-(2—chloro—G—fluorophenyI)(1-(dimethylamino)—3«oxopropen—2- yl)isoxazolecarboxylate 0 9H3 i \ / CI ‘CHs Methyl 3 —(2—chloro~6mfluorophenyl)—5-(1—(dimethy1amino)-3—oxoprop-lien—2—yl)isoxazole—4— carboxylate was synthesized from methyl hloro-6~fluorophenyl)~5—(2» (dimethylamino)vinyl)isoxazole—4-carboxylate using a Vilsmeier formulation in analogy to Tetrahedron Left. 1988, 29, 233 9.

HZN‘NH 9H3 ,CH3 Pb GP 0 N fl—\ be S \ ”t? O M we To a solution of raw methyl hloro-6—fluorophenyl)—5—[2-(dimethylamino)~1— formylvinyl]isoxazole-4—carboxylate (36 mg, 0.102 mmol) in ethanol (460 mg), 2~ fluorophenyl hydrazine hydrochloride (16 mg, 0.100 mmol) was added. The mixture was warmed to 55~60°C until a TLC sample showed no starting enamine. The solution was evaporated to dryness in vacuum, the reside was extracted with 3 x 10 ml of boiling hexane, and the hexane extracts were combined and trated and cooled to room temperature.

Crystallization gave 25 mg of desired product (example I—89) (yield 60%). Result of LC/MS MH+z 416,05; 1H NMR (CDC13)I 3,67 (s, 3 H), 7,30 (t, 1H), 7,45 (m, 4H), 7,57 (m, 1H), 7,93 (t, 1H), 8,50 (s, 1H), 9,13 (s, 1H).

Further examples which were obtained in analogy to the protocol of example I—89 are: [-2115, and 13-21.

Synthesis of methyl hloro~6—fluorophe'nyl)—5—{[1—(4—methoxycarbonyI(4- ch10rophenyl)isoxazol—5-yl)trifluoromethyl—1H-pyrazol-4—yl] }-isoxazole—4-carboxylate (example I—13I) CI CI Cl 0 0 PH?! /CH3 0 /CH3 0 O O POC|3 N/ EtsN N/ \ N/ \ A) Methyl S-chloro—S—(4—chlorophenyl)isoxazolecarboxylate.

A suspension of methyl 3-(4-chlorophenyl)~5—oxo—4,5~dihydroisoxazole—4-carboxylate (518mg, 2.04mmol', ng block is commercially available) in POC13 (3mL) was cooled to 0-50C, and upon stirring, Eth (0.3mL) was added dropwise. The resulting mixture was heated to 100—1 10°C and stirred at this temperature for 2—25 h, cooled to room temperature, poured into iced water and neutralized with aqueous NaOH (10%). The product was extracted with ether and d by column tography (hexane:EtOAc 25:2) to give 320mg of a yellow solid. Yield 57%. 1H NMR (DMSO—D6, CC14): 3.79 (3H, s, OCH3), 7.50 (211, AB- syst., CH—arom.), 7.65 (2H, AB—syst., CH—arom.).

B) Methyl 3-(4-chlorophenyl)hydrazinoisoxazole-4~carboxylate.

To an ice cooled solution of hydrazine hydrate in MeOl-l (0.3mL in SmL) methyl S—chloro (4-chlorophenyl)isoxazolewtt-carboxylate (0.3 g, 1.1mmol) dissolved in CH2C12 (2mL) was added dropwise. The reaction mixture was stirred for 2h and half of the solvent was evaporated. The product was filtered off, washed with cold methanol and dried to give 227mg (77%) of 5—hydrazinoisoxazole. 1H NMR (DMSO—D6, CCl4): 3.1 (3H, bs, NH+H20), 3.64 (3H, s, OCH3), 4.65 (2H, bs, NHZ), 7.43 (2H, t., CH—arom.), 7.60 (2H, AB-syst., CH- arom.).

C) Methyl 3-(2—chloro-G-fluorophenyI){[1-(4—methoxycarbonyl—3-(4- phenyl)is0xazol~5-yl)-5—trifluoromethyl-1H~pyrazol—4-yl]}~isoxazole—4-carboxylate (example 1—131) The mixture of methyl 3—(2—chlor0—6—fluorophenyl)-5—(l~(dimethylamino)-4,4,4strifluoro—3- oxobut—l~en—2—yl)isoxazolecarboxylate (157 mg, 0.37 mmol) and methyl 3—(4w chlorophenyl)—5—hydrazinoisoxazole-4—carboxylate (0.1 g, 0.37 mmol) in ethanol (1 mL) was heated at 60°C for 5 h, the solution was evaporated and the product was crystallized from methanol to give 86mg (37%) of example I-13I. 1H NMR (DMSO-Dé, CC14): 3.69 (3H, OCH3), 3.71 (3H, s, OCHS), 7.35 (1H, dd, CH-arom.), 7.47 (1H, d, CH—arom.), 7.57 (2H, t., CH—arom.), 7.63 (1H, m, CPI—atom), 7.84 (2H, AB—syst., CPI-atom), 8.74 (1H, s, CH pyrazol.). sis of methyl 3-(chhlorofluorophenyl)(5—(ethoxycarbonyl)phenyl—1H~ pyrazol—4—yl)isoxazoIe-4—carboxylate derivatives: examples 1—6, 1-8, 1-9, I—10, 1-13, 1-15, I~ 26, 1-29, 1—34, 1—35, 1-38, 1-39, 1-40, 1-41 and 1—45 Starting from methyl 3—(2—chloro~6—fluorophenyI)-5—(1—(dimethylamino)-4—ethoxy—3,4- ut-l—en—2—yl)isoxazole—4—carboxylate, which is commercially available from Bioner WO 01263 ch Intermediates, the pyrazole ring was constructed using differently substituted arylhydrazines as described for example 1-11.

Analytic: Abbreviations: min, minute(s); 11, hour(s); r.t., room temperature; Rt, retention time; ‘1’, pseudo; s, singlet; t, triplet, quint, t; br., broad; J, coupling constant; pTLC, preparative thin layer chromatography; DMAP, 4-dimethylaminopyiidine.

Analfiical TLC: Merck aluminium sheets, silica gel 60 F254.

Preparative TLC: Merck PLC , silica gel 60 F254, 05 mm, 1.0 mm or 2.0 mm.

Flash chromatogzaphy: Acros silica gel 60A, 0.035 — 0.070 mm. Flash Master Personal or Flash Master H, Jones Chromatography, UK.

NMR spectra: Bruker Avance 300 MHZ. The IlrI NMR spectra were recorded at 300 MHz; concentration, 1 to 5 mg/mL; ature, 305 K. The 13 C NMR spectra at 75.5 MHZ; concentration, 5 to 20 mg/mL; temperature, 305 K. The residual solvent peaks were used as the internal rds (DMSO—dg: 5H 2.49, 5c 39.5; CDC13: 5 H 7.24, 5 C 77.0; CD30D: 5 H 3.30, 5 c 49.0). Alternatively, TMS was used as a standard (indicated with TMS).

Analfiical LC/ESI—MS: Waters 2700 Autosampler. 2 x Waters 600 Multisolvent Delivery System, Waters 600 Controller. 50 pl. sample loop. Column, lith Speed ROD RPlSe (Merck, Darmstadt), 50 x 4.6 mm, with 2 um prefilter (Merck). Eluent A, H20 + 0.1% HCOgH; eluent B, MeCN. Gradient, 2 % B to 100 % B Within 4 min, then isocratic for 0.90 min, then back to 2 % B Within 0.15 min, then tic for 0.50 min; flow, 3 mL/min. Waters LCZ single pol mass spectrometer with electrospray source. MS method, MSSminPM» 80—800-20V; positive/negative ion mode scanning, m/z 80 — 800 or 80 — 900 in 1 s; capillary, 3.5 kV; cone voltage, 20 V; multiplier voltage, 400 V; probe and desolvation gas temperature, 1200 C and 350° C, respectively. Waters 2487 Dual 7L Absorbance or, set to 254 nm.

Software, Waters Masslynx V 4.0. Values for [M+H]+ given in the Tables 1 and 2 are calculated exact mass values for the specific compound upon protonation, values found Within the corresponding LC/MS chromatogram were all within tolerable margins of +/~ 0.3. ative HPLC-MS: Waters 2700 Autosampler, Waters 600 Multisolvent Delivery System with preparative pump heads, Waters 600 Controller, 5000 uL Sample loop. At-column dilution: Waters 600 Multisolvent Delivery System with analytical pump heads; Waters 600 Controller; solvent, MeCN - MeOl—l 80 : 20 (v/v); flow rate, 0.20 or 1 mL/min. Column, Waters X—Terra RP18, 7 um, 19 x 150 min with X—Terra RP18 guard cartridge 7 um, 19 X 10 mm, used at flow rate 20 lnL/min. Eluent A, H20 containing 0.1 % (v/v) HCOZH or H20 ning 0.1 % (v/V) NEt3; eluent B, MeCN. Difierent linear gradients, individually adapted to sample. Injection volume, 0.5 mL — 5 mL, depending on sample. Make—up solvent, MeOH MeCN - H20 ~ HCOgH 80 : 15: 4.95 : 0.05 (V/vXV/V). Makenup pump, Waters Reagent Manager, flow rate 0.5 . Waters ZQ single quadrupol mass ometer with electrospray source. Positive or negative ion mode scanning m/z 105 — 950 in 1 s; capillary, 4 kV; cone voltage, 20 V; multiplier voltage, 600 V; probe and ation gas temperature, 12000 and 250°C, respectively. Waters Fraction Collector II with riggered fraction collection. Waters 2487 Dual 7L Absorbance Detector, set to 254 nm. Software, Waters Masslynx V 4.0.

Analysis of proliferation of and Cytokine production by human PBMC stimulated with eral blood mononuclear cells (PBMC) from healthy human donors were purified using AccuspinTM System—Histopaquem1077 (Sigma) according to the protocol recommended by the cturer. Purified PBMC were then washed twice with phosphate-buffered saline (PBS) and resuspended in RPM11640 culture medium supplemented with 10% dialyzed heat vated fetal calf serum, 1.5 mM L—glutamine, 100 U penicillin/ml, and 100 mg streptomycin/ml (all from PAN Biotech, Aidenbach, Germany). For stimulation, PBMC were seeded at 1 X 105 cells/well, activated with 2 ug/ml phytohaemagglutinin (PHA, Sigma) and incubated with the test compounds for 48 hours. IL-17A, IL—17F and INF-y were then determined in the culture supernatant using a x BioPlex system, following the manufacturer’s instructions (BioRad, Munich, Germany). For screening, compounds were used at 10, 1, 0.1 and 0.01 uM. To determine the 1050, compounds were titrated semiiogarithrnically.

Cell proliferation was analysed using the BrdU based cell proliferation ELISA from Roche (Mannheim, Germany) according to the manufacturer’s instructions.

Cytokines were ined in the aforementioned culture supernatant using the following methods: IL—l7AA/AF was ed using the Luminex BioPlex system (BioRad, , Germany); IL-17AA using the human homodimer lL—17A ELISA Ready Set Go Kit from eBioscience (Frankfurt, y); IL-17FF using the human IL—17F ELI-Pair from Hélzel DiagnosticaGmBH (Kc-in, Germany); and IFN-y using the OptEIA human IFN—g ELISA from BD ence (Heidelberg, Germany), all following the manufacturer’s instructions.

T cell proliferation assay Peripheral blood mononuclear cells (PBMC) from healthy human donors were isolated by centrifugation over Ficoll-Hypaque (Sigma~Aldrich, Germany) according to manufacturer’s instructions. Purified PBMC were washed twice with PBS and resuspended in RPM11640 culture medium supplemented with 10% dialyzed heat inactivated fetal calf serum, 1.5 mM L~glutamine, 100 U penicillin/ml, and 100 mg streptomycin/ml (all from PAN Biotech, Aidenbach, Germany). For stimulation, PBMC were seeded at 1 x 105 cells/well, activated with 2 rig/ml aemagglutinin (PHA, Sigma) and incubated with the test compound.

After 48 hours proliferation was measured using the BrdU based cell proliferation ELISA from Roche eim, Germany) according to the manual.

Claims (1)

1. CLAIMS 157157 R” independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, -N=C(R’)2, -NR’-CO-R’, -CR’O, -C02R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’; A compound according to claim 1, wherein Ar is aryl or heteroaryl, which can be tuted by one or more substituents R’; 10 R1, Z, Y, R’ and R” are as defined in claim 1. A compound according to claim 1, wherein R1 is aryl or heteroaryl, which can be substituted by one or more substituents R’ Ar is aryl or heteroaryl, which can be tuted by one or more tuents R’; Z, Y, R’ and R” are as defined in claim 1. 20 A compound according to claim 1, wherein R1 is aryl or heteroaryl, which can be substituted by one or more substituents R’ Ar is aryl or heteroaryl, which can be substituted by one or more substituents R’; Z is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R’; Y is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more 30 tuents R’; R’ independently represents H, , -CONHR”, -CR”O, -SOzN(R”)2, - ”, -CN, alkyl, cycloalkyl, aminoalkyl, alkoxy, -OH, , hydroxyalkyl, halogen, haloalkyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; R’’ independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, 5 -N=C(R’)2, -NR’-CO-R’, -CR’O, -CO2R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R’. 5. A compound according to claim 1, wherein R1 is aryl or heteroaryl, which can be substituted by one or more substituents R’; Ar is aryl or aryl, which can be substituted by one or more substituents R’; 15 Z is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R’; Y is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R’; R’ ndently ents H, -CO2R’’, -SO2N(R’’)2, -SO2NHR’’, -CN, alkyl, alkoxy, -OH, hydroxyalkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl; 25 R’’ independently represents H, kyl, hydroxyalkyl, amino, alkoxy, -N=C(R’)2, -NR’-CO-R’, -CR’O, -CO2R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, cyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more tuents R’. 30 6. A compound according to claim 1, wherein R1 is aryl or aryl, which can be substituted by one or more substituents R’; Ar is aryl or heteroaryl, which can be substituted by one or more substituents R’; Z is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R’; 5 Y is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R’; R’ independently represents H, -CO2R’’, -CONHR’’, -CR’’O, -SO2N(R’’)2, - ’’, -CN, alkyl, alkoxy, -OH, halogen, haloalkyl or haloalkoxy,; R’’ independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, -N=C(R’)2, -NR’-CO-R’, -CR’O, -CO2R’, alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are ally substituted by one or more substituents R’. 7. A compound according to any one of claims 1 to 6, wherein R1 is selected from the group comprising phenyl which is optionally substituted by one or more substituents individually selected from oromethyl, ne, 20 chlorine, bromine, nitro, NH2, -CN, -NHCO-C1alkyl, methoxy, C1alkyl, - SO2NH2, or -SO2NH-C1alkyl; pyridyl which is optionally substituted by one or more of the aforementioned substituents for phenyl; pyrimidyl which is optionally substituted by one or more of the aforementioned tuents for phenyl; thienyl which is optionally substituted by one substituent–COO-C1- 25 4alkyl; 1,1-dioxo-tetrahydrothienyl, 2,2,2-trifluoroethyl, isopropyl, isobutyl, 2- yethyl, tetrahydropyranylmethyl, 2-morpholinoethyl, pyridin ylmethyl and ydrofuranylmethyl; Ar is selected from the group comprising phenyl and pyridyl, which can be 30 substituted by one or more tuents independently selected from fluorine methoxy or chlorine; Z is selected from the group comprising phenyl or heteroaryl, which can be substituted by one or more substituents selected from the group comprising C1- 4alkyl, C1-4haloalkyl, hydrogen, hydroxyl, C1-4alkoxy, and C1-4alkoxycarbonyl; 5 Y is selected from the group comprising H, oromethyl and methoxycarbonyl. 8. A compound according to any one of claims 1 to 6, wherein 10 R1 is selected from the group comprising phenyl which is optionally substituted by one or more substituents individually selected from fluorine, chlorine, bromine, nitro, NH2, -CN, -NHCO-C1alkyl, methoxy, t-butyl, -SO2NH2, or -SO2NH- pyl; pyridyl; pyrimidyl which is optionally substituted by one or more substituents selected from methyl or trifluoromethyl; thienyl which is 15 optionally substituted by one substituent–COO-methyl, 1,1-dioxotetrahydrothienyl , trifluoroethyl, isopropyl, yl, 2-methoxyethyl, tetrahydropyranylmethyl, 2-morpholinoethyl, pyridinylmethyl and tetrahydrofuranylmethyl; 20 Ar is selected from the group comprising phenyl, 2,6-difluorophenyl, 2-chloro fluorophenyl, 2-chloromethoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2,6- dichlorophenyl, 2,4-dichlorophenyl, 3-fluoropyridinyl, chloropyridin- 4-yl and 3,5-difluoropyridinyl; 25 Z is selected from the group comprising phenyl, tetrazolyl, thiazolyl, 1,3,4- oxadiazolyl, oxazolyl, 1,3,4-thiadiazolyl, furanyl, and enyl, which can be substituted by one or more substituents selected from the group comprising , trifluoromethyl, hydrogen, hydroxyl, y, and methoxycarbonyl and ethoxyoxycarbonyl; Y is selected from the group comprising H, trifluoromethyl and methoxycarbonyl. 9. A compound according to any one of claims 1 to 6, wherein R1 is selected from the group comprising phenyl, 2-fluorophenyl, 2- methoxyphenyl, 2-chlorophenyl, 2-bromophenyl, 2-nitrophenyl, 2- 5 aminophenyl, rophenyl, 4-tertbutylphenyl, 3-fluorophenyl, 3- chlorophenyl, 3-cyanophenyl, 3-acetamido-phenyl, 2-acetamido-phenyl, 3- aminosulfonyl-phenyl, 3-(isopropylamino)sulfonyl-phenyl, 3-nitrophenyl, 3- aminophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 2,3,5,6-tetrafluorophenyl, 2-pyridyl; 3-pyridyl; 4-pyridyl; 4- trifluoromethyl- 10 pyrimidyl, 2,6-dimethyl-pyrimidyl, 2-methoxycarbonyl-thienyl, 1,1- dioxo-tetrahydrothienyl, 2,2,2-trifluoroethyl, isopropyl, isobutyl, 2- methoxyethyl, ydropyranyl-methyl, 2-(morpholinyl)-ethyl, and tetrahydrofuranyl-methyl; 15 Ar is ed from the group sing , 2-chlorofluorophenyl, 2- fluorophenyl, rophenyl, 2,6-dichlorophenyl, 2,4-dichlorophenyl, 3- fluoropyridinyl, and 3,5-difluoropyridinyl; Z is selected from the group comprising 1H-tetrazolyl, 4-methylthiazolyl, 20 thiazolyl, 5-(trifluoromethyl)-1,3,4-oxadiazolyl, 5-methyl-1,3,4- oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, 4-hydroxy-thiazolyl, 4- y-thiazolyl, 5-methyl-1,3,4-thiadiazolyl, 1,3,4-thiadiazolyl, furanyl, furanyl, thiophenyl, phenyl, 4-methoxycarbonyl-thiazolyl, and 4-ethoxycarbonyl-thiazolyl; Y is selected from the group comprising H, trifluoromethyl and methoxycarbonyl. 10. A compound according to any one of claims 1 to 10, wherein the compound is selected 30 from the group comprising the compounds 162162 2-(3-(2-chlorofluorophenyl)(1 -(3¥fluorophenyl)(trifluor0methyl)-1H-pyrazol- 4-y1)isoxazol—4—y1)(trifluoromethyl)- 1 ,3,4-oxadiazole, 2—(3-(2-chloroflu0ropheny1)(1-(3-fluorophenyl)(triflu0r0methy])-lH-pyrazol- 4-yl)isoxazolyl)-1,3 ,4-oxadiazole, 3-(2—chlorofluoropheny1)(1-(3-chlorophefiyl)—5-(trifluoromethy1)-1H—pyrazol yl)(0xazolyl)isoxazole, 3-(2-chlorofluoropheny1)—5-(1 -(3-fluoropheny1)(triflu0romethy1)-1H-pyrazol yl)—4-(4-methoxythiazoly1)isoxazole, 2»(3-(2-chlorofluorophenyl)-S-(1-(2-fluorophenyl)(trifluoromethyl)-1H-pyrazol- 4-y1)isoxazolyl)methy1-1 ,3 ,4-oxadiazole, 3-(2-chlorofluoropheny1)-5—(1—(2—fluorophenyl)—5—(tfifluoromethyl)—1H—pyrazol—4— yl)(5-methy1-1,3 ,4-thiadiazol-Z-y1)isoxazole, 3-(2-ch10rofluorophenyl)(1-(3-fluorophenyl)(trifluoromethyl)-1H-pyrazol yl)-4»pheny1isoxazole, 3-(2-chlorofluoropheny1)-5 —(l -(3-fluoropheny1)-5—(trifluor0methyl)—1H-pyrazol—4- yl)(thi0phen-3 oxazole, _ 3-(2-chloro-6—fluorophenyl)(1-(3-fluoropheny1)-5—(triflu0romethyl)-1H-pyrazol y])(furany1)isoxazole, methyl 2-(3-(2-chloro-6—fluoropheny1)—5-(1-(3-fluoropheny1)(triflu0romethyl)-1H- pyrazolyl)isoxazol-4—y1)thiazole—4-carboxylate, 3-(2-chlorofluoropheny1)—5 -(1 -(3-chlorophenyl)(trifluoromethy1)- lH-pyraz'ol-4— y1)(5-methyl-1 hiadiazolyl)isoxazole, 2-(3-(2-chlorofluor0phenyl)(1-(3-chlorophenyl)(trifluoromethy1)-lH-pyrazol- 4-y1)isoxazoly])—5-methyl-1,3 ,4-oxadiazole, 2—(3-(2-chlorofluor0phenyl)-S-(1-(3-chlorophenyl)(trifluoromethy1)—1H-pyrazol- 4-y1)isoxazol—4-yl)-1,3 ,4-oxadiazole, h]0ro-6—fluorophenyl)(1-(3-chloropheny1)(trifluoromethy1)-1H—pyrazol (furanyl)isoxazole, 3-(2-chlorofluoropheny1)(1-(3-chloropheny1)(trifluoromethy1)—1H—pyrazol yl)(furan-3 -y1)isoxazole, 3-(2-chloro-6—flu0ropheny1)-5—(1-(3—cthropheny1)(trifluoromethyl)-1H-pyrazol-4— yl)(l ,3 adiaz0lyl)isoxazole, 3—(2—chlorofluorophenyl)(1 -(2-fluor0phenyl)—5-(trifluoromethy1)-1H—pyrazol y1)(furan-3 -y1)isoxazole, 11. A compound according to any one of claims 1 to 10 for use as a medicament. 12. A compound according to any one of claims 1 to 10 for use in the treatment of a disease or indication is selected from the group consisting of psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave’s disease, rheumatoid arthritis, vitiligo, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet e, atopic dermatitis, Lichen planus, n’s syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host s- Graft-Reaction and osteoarthritis. 13. Use of the compounds of the formula (I) as defined in any one of claims 1 to 10, and of their cologically tolerable salts in the cture of a medicament for use in treatment of a disease or a therapeutic indication in which the inhibition of interleukin-17 (IL-17) and/or Interferon-γ (INF-γ) is beneficial. 14. The use of claim 13 wherein the disease or indication is selected from the group consisting of psoriasis, psoriatric tis, autoimmune thyroiditis, Grave’s disease, rheumatoid arthritis, vitiligo, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, sing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjögren’s syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, 5 Host -versus-Graft-Reaction and osteoarthritis. 15. A compound according to claim 1 ntially as herein described or exemplified. 16. A use according to claim 13 substantially as herein described or exemplified.